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Abstract——The P2X7 receptor is a trimeric ATP-gated
cation channel found predominantly, but not exclusively,
on immune cells. P2X7 activation results in a number of
downstream events, including the release of proinflammatory mediators and cell death and proliferation. As
such, P2X7 plays important roles in various inflammatory,
immune, neurologic and musculoskeletal disorders. This
review focuses on the use of P2X7 antagonists in rodent
models of neurologic disease and injury, inflammation,
and musculoskeletal and other disorders. The cloning and
characterization of human, rat, mouse, guinea pig, dog,
and Rhesus macaque P2X7, as well as recent observations

regarding the gating and permeability of P2X7, are
discussed. Furthermore, this review discusses polymorphic and splice variants of P2X7, as well as the generation
and use of P2X7 knockout mice. Recent evidence for
emerging signaling pathways downstream of P2X7 activation and the growing list of negative and positive
modulators of P2X7 activation and expression are
also described. In addition, the use of P2X7 antagonists in numerous rodent models of disease is extensively
summarized. Finally, the use of P2X7 antagonists in clinical
trials in humans and future directions exploring P2X7 as
a therapeutic target are described.

I. The P2X7 Receptor

of the related zebrafish P2X4 receptor (Gonzales et al.,
2009; Kawate et al., 2009). To the best of our knowledge,
similar modeling experiments have not been carried
out for rodent or canine P2X7 receptors. However, the
structures of rodent and canine P2X7 receptors are
likely to be similar to that of primate P2X7, as these
receptors share 77–85% sequence identity to human
P2X7 (Table 1). Furthermore, the study of native rat P2X7
complexes supports the trimeric arrangement of rodent
P2X7 (Nicke, 2008). More recently, the crystal structure of
the zebrafish P2X4 receptor in complex with ATP has
been reported (Hattori and Gouaux, 2012). This agonistbound structure provides new insights into the mechanism of P2X receptor activation and may be useful for the
development of new pharmacological agents.
Activation of P2X7 by extracellular ATP allows for the
passage of small cations, including Ca2+, Na+, and K+,
across the plasma membrane (Surprenant et al., 1996;
Rassendren et al., 1997; Chessell et al., 1998). However,
prolonged ATP stimulation leads to the formation of a
larger reversible pore, which allows for the uptake of
organic ions (Steinberg and Silverstein, 1987; Surprenant
et al., 1996; Rassendren et al., 1997; Chessell et al.,
1998) (see section VI). Activation of P2X7 by ATP, or the
alternate, rodent-specific ligand nicotinamide adenine
dinucleotide (NAD), results in a number of cell-specific

A. Structure and Function of the P2X7 Receptor
ATP and other nucleotides, as well as nucleosides, are
important extracellular signaling molecules that operate
through a complex purinergic signaling network
(Burnstock, 1972, 2006). This network is composed of a
number of membrane receptors and ectoenzymes, which
includes the P2X7 receptor (Yegutkin, 2008). The P2X7
receptor is encoded by the P2RX7 gene and belongs to the
P2X family of trimeric ligand-gated cation channels,
of which there are seven distinct members (P2X1–7)
(Coddou et al., 2011). Of the P2X family, the P2X7
monomeric subunit is the largest, with a length of 595
amino acids for the human, rat, mouse, dog, and Rhesus
macaque receptors (Surprenant et al., 1996; Rassendren
et al., 1997; Chessell et al., 1998; Roman et al., 2009;
Bradley et al., 2011b). Each subunit is characterized by
relatively short and long intracellular amino and carboxyl
(C) termini, respectively, as well as two hydrophobic
membrane-spanning segments (transmembrane domains)
separated by a long glycosylated extracellular ATP-binding
domain. The trimeric structures of the human and Rhesus
macaque P2X7 receptors are supported by atomic
computer modeling (Roger et al., 2010b; Bradley et al.,
2011b; Jiang et al., 2013), based on the crystal structure

ABBREVIATIONS: A438079, 3-[[5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl]methyl]pyridine; A740003, N-(1-([(cyanoimino)(5-quinolinylamino)
methyl] amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide; A839977, 1-(2,3-dichlorophenyl)-N-[[2-(2-pyridinyloxy)phenyl]
methyl]-1H-tetrazol-5-amine; AACBA, N-(adamantan-1-ylmethyl)-5-[(3R-amino-pyrrolidin-1-yl)methyl]-2-chloro-benzamide; ART,
ADP-ribosyltransferase; ATPgS, adenosine-59-O-(3-thiotriphosphate); AZ10606120, N-[2-[[2-[(2-hydroxyethyl)amino]ethyl]amino]-5quinolinyl]-2-tricyclo[3.3.1.13,7]dec-1-ylacetamide; AZ11645373, 3-[1-[[(39-nitro[1,1’-biphenyl]-4-yl)oxy]methyl]-3-(4-pyridinyl)propyl]2,4-thiazolidinedione; BBG, Brilliant Blue G; BzATP, 29(39)-O-4-benzoylbenzoyl)-ATP; CE-224,535, 2-(4-chloro-3-[3-(1-hydroxycycloheptyl)
propanoyl]phenyl)-4-[(2R)-2-hydroxy-3-methoxy-propyl]-1,2,4-triazine-3,5-dione; CFA, complete Freund’s adjuvant; GSK1370319A, N[(2,4-dichlorophenyl)methyl]-1-methyl-5-oxo-l-prolinamide; GSK, GlaxoSmithKline; HEK, human embryonic kidney; IL, interleukin; IFN-g,
interferon-g; JNJ-47965567, N-([4-(4-phenyl-piperazin-1-yl)tetrahydro-2H-pyran-4-yl]methyl)-2-(phenyl-thio) nicotinamide; KN-62, 1-[N,O-bis
(5-isoquinolinesulfonyl)-N-methyl-l-tyrosyl]-4-phenylpiperazine; KO, knockout; LPS, lipopolysaccharide; MED1011, 2-[1-(6-amminopurin-9-il)-2osso-etossi]prop-2-enale; 2MeSATP, 2-methylthio-ATP; NAD, nicotinamide adenine dinucleotide; NCBI, National Center for Biotechnology
Information; oATP, periodate-oxidized ATP; PGE2, prostaglandin E2; PPADS, pyridoxal phosphate-6-azophenyl-2-4-disulfonic acid; ROS, reactive
oxygen species; SNP, single nucleotide polymorphism; Sp1, specificity protein 1 transcription factor; TM2, second transmembrane domain; TNF-a,
tumor necrosis factor-a; WT, wild-type.
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TABLE 1
Agonist profiles of mammalian P2X7
Species

Sequence
Identity

EC50
References
ATP

BzATP
mM

%

Human
Rhesus macaque
Dog
Rat
Mouse (BALB/c)
Mouse (C57BL/6)
Guinea pig

100
96
85
80
80
80
77

ATPgS

96
800
1148
85
200
162
603

5
58
21
4
60
36
.200

.100
N.D.
N.D.
.1000
.1000
.1000
N.D.

Bianchi et al., 1999
Bradley et al., 2011b
Roman et al., 2009
Surprenant et al., 1996
Donnelly-Roberts et al., 2009
Donnelly-Roberts et al., 2009
Fonfria et al., 2008

N.D., not determined.

downstream signaling events, many of which were
established or are supported by rodent models of disease
(see sections VII and X). These downstream signaling
events are dependent on a variety of factors, including
cell type, extracellular conditions, and the concentration
of extracellular ATP (Burnstock, 2007). The presence of
ectonucleotidases, which degrade ATP and other nucleotides, regulate the concentration and duration of availability of P2 receptor agonists in the extracellular space
(Yegutkin, 2008). Thus, P2X7 receptors are possibly only
activated after injury, infection, or in tumor microenvironments when the concentration of ATP increases
locally or when ectonucleotidases are downregulated
(Lenertz et al., 2011). Alternatively, it is possible that
currently unknown allosteric modulators might act on
P2X7 in vivo to decrease its Km for ATP, thus allowing
the activation of P2X7 at lower nucleotide concentrations.
There is also emerging evidence that P2X7 activation
stimulates ATP release, further complicating the study
of the ATP/P2X7 signaling axis. P2X7-mediated ATP
release has been observed from human embryonic kidney
(HEK)-293 cells transfected with rat or human P2X7
(Pellegatti et al., 2005), from astrocytes during Ca2+ signal
transmission (Suadicani et al., 2006), from osteoclasts
undergoing fusion (Pellegatti et al., 2011) and in culture
(Brandao-Burch et al., 2012), and from melanoma cells
after g-irradiation (Ohshima et al., 2010).
B. Distribution of the P2X7 Receptor
P2X7 is widely distributed throughout the mammalian
body (see Burnstock and Knight, 2004). This receptor
was originally thought to be restricted to cells of the
hematopoietic lineages; this includes macrophages, dendritic cells, monocytes, lymphocytes, and erythrocytes, as
well as osteoclasts, mast cells, and eosinophils. However,
it is now evident that P2X7 is present on cells from other
lineages, including osteoblasts, fibroblasts, endothelial
cells, and epithelial cells. Furthermore, P2X7 is present
on cells in the central and peripheral nervous systems,
including microglia, astrocytes, oligodendrocytes, and
Schwann cells (Sperlágh et al., 2006). In addition, there
are reports of the presence of P2X7 on some populations
of neurons, including those from the spinal cord, cerebellum, hypothalamus, and substantia nigra (see Lenertz

et al., 2011; Wiley et al., 2011). Although P2X7 has been
identified on a number of cell types, less is known about
the relative distribution of P2X7 between different cell
types within whole tissues. Recently, transgenic P2X7
reporter mice expressing enhanced green fluorescent
protein downstream of the P2RX7 promoter have been
generated (Engel et al., 2012; Garcia-Huerta et al., 2012;
Jimenez-Pacheco et al., 2013), which is an important step
toward addressing the distribution of P2X7 in vivo. For
example, these mice have been used to localize P2X7
expression in the central nervous system after prolonged
seizures, with P2X7 identified to be upregulated on
neurons, but not upregulated on microglia or astrocytes,
in the hippocampus and neocortex (Engel et al., 2012;
Jimenez-Pacheco et al., 2013). Although the P2X7 expression on microglia and astrocytes was weak in these
studies, P2X7 expression in these cell types is well
established from immunohistochemical studies (see
Verkhratsky et al., 2012). In addition, transgenic P2X7
green fluorescent protein reporter mice have been used
to localize P2X7 on cells from the cerebral cortex and
pons of newborn mice (Engel et al., 2012; Garcia-Huerta
et al., 2012). P2X7 expression was also demonstrated in
peritoneal macrophages and the spleen, validating the
reliability of these mice (Garcia-Huerta et al., 2012).
C. The P2X7 Receptor in Health and Disease
P2X7 has been associated with a number of diseases
(see Miller et al., 2011; Sluyter and Stokes, 2011;
Volonté et al., 2012). In particular, a number of human
P2X7 single nucleotide polymorphisms (SNPs) or
haplotypes that decrease or increase receptor function
have been associated with various infectious, musculoskeletal, psychiatric, inflammatory, and cardiovascular diseases (see section VIII). In addition to diseases
associated with SNPs, studies of human tissue or
mouse models suggest that P2X7 may play important
roles in a number of inflammatory, immune, neurologic,
or musculoskeletal disorders. Such disorders include
multiple sclerosis (Yiangou et al., 2006), amyotrophic
lateral sclerosis (Yiangou et al., 2006), Alzheimer’s
disease (Ryu and McLarnon, 2008; Diaz-Hernandez
et al., 2012), Huntington’s disease (Díaz-Hernández
et al., 2009), cancer (Ghiringhelli et al., 2009; Adinolfi
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et al., 2012), ischemia (Arbeloa et al., 2012; Chu et al.,
2012), neuropathic and inflammatory pain (Chessell
et al., 2005), rheumatoid arthritis (Portales-Cervantes
et al., 2010; Bhattacharya et al., 2011), glomerulonephritis
(Taylor et al., 2009b), pulmonary fibrosis (Riteau et al.,
2010), and graft-versus-host disease (Wilhelm et al., 2010).
Given the potential importance of P2X7 in health
and disease, considerable effort has gone into characterizing the presence and function of mammalian P2X7
receptors, and into the generation of selective P2X7
antagonists and the investigation of the potential therapeutic efficacy of such compounds in rodent models of
disease. This paper aims to review recent developments
regarding mammalian P2X7 receptors, with an emphasis
on the use of P2X7 antagonists in rodent models of disease.
II. The Rodent P2X7 Receptor
Rodent P2X7 was first cloned from rat brain (Surprenant
et al., 1996), followed by the cloning of P2X7 from NTW8
murine microglia soon after (Chessell et al., 1998).
Compared with other P2X receptors, P2X7 requires at
least one log higher ATP concentrations for activation
(Table 1). Within this concentration range, ATP induces
channel and pore formation in cells transfected with
recombinant rat or mouse P2X7 (Surprenant et al.,
1996; Chessell et al., 1998). With recombinant rat P2X7,
the agonist order of potency was 29(39)-O-4-benzoylbenzoyl)ATP (BzATP) .. ATP . 2-methylthio-ATP (2MeSATP) .
adenosine-59-O-(3-thiotriphosphate) (ATPgS) .. ADP
(Surprenant et al., 1996). However, a more recent studied
failed to confirm 2MeSATP and ATPgS as agonists of rat
P2X7 (Donnelly-Roberts et al., 2009). Moreover, this
same study failed to establish these same two nucleotides
as agonists of murine P2X7 (Donnelly-Roberts et al.,
2009). Notably, there are reported differences in P2X7
agonist sensitivities between these two species, with rat
P2X7 being 10-fold more sensitive to BzATP and ATP
than mouse P2X7 (Young et al., 2007).
In rodents, P2X7 can also be activated via a unique
ATP-independent pathway involving the transfer of an
ADP-ribose group from NAD to P2X7 (Adriouch et al.,
2001; Seman et al., 2003). ADP-ribosylation, a posttranslational modification of proteins, is an important
regulatory mechanism. In prokaryotes, ADP-ribosylation
of target proteins is responsible for the adverse effects of
a number of bacterial toxins in host cells (Ludden, 1994;
Aktories, 2011). In eukaryotes, ADP-ribosylation has
been implicated in transcriptional regulation, cell division, intracellular energy metabolism, neuronal signaling, and inflammation (Abd Elmageed et al., 2012;
Hassler and Ladurner, 2012). Similar to ATP-induced
P2X7 activation, NAD-induced activation of P2X7 results
in Ca2+ flux, pore formation, phosphatidylserine exposure, shedding of CD62L, cell shrinkage, DNA fragmentation, and apoptosis (Adriouch et al., 2001; Seman et al.,
2003). These NAD-induced P2X7 responses are observed
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in T cells, but they are not observed in macrophages
(Adriouch et al., 2001; Hong et al., 2009). However,
although the majority of studies investigating NADinduced activation of P2X7 have been performed with
murine T cells, there is also evidence that this pathway
occurs in murine astrocytes (Wang et al., 2012) and rat
retinal microvessels (Liao and Puro, 2006). Although
NAD induces similar downstream events to that seen
after ATP-induced activation of P2X7, much lower NAD
concentrations are required for receptor activation compared with ATP (EC50 for phosphatidylserine exposure 2
and 100 mM, respectively) (Seman et al., 2003). It is
noteworthy that NAD and ATP, released through the lysis
of erythrocytes, are able to activate P2X7, suggesting that
sufficient concentrations of these ligands can be released to
activate P2X7 within rodents (Scheuplein et al., 2009).
The transfer of ADP-ribose from NAD to P2X7 is
catalyzed by the cell-surface ectoenzyme ADPribosyltransferase (ART) 2 (Adriouch et al., 2001), the
crystal structure of which has been determined for rat
(Mueller-Dieckmann et al., 2002). Of note, this pathway
of P2X7 activation does not occur in humans because of
the absence of ART2 orthologs (Haag et al., 1994). In
rodents, there are two isoforms of ART2, termed ART2.1
and ART2.2. These isoforms are thought to play a role in
the reported differences in sensitivities to NAD-mediated
P2X7 activation between mouse strains and cell types.
First, NAD induces Ca2+ flux, but not apoptosis, in T cells
derived from C57BL/6 mice, whereas both these NADmediated P2X7 responses are observed in T cells derived
from BALB/c mice (Adriouch et al., 2001; Hong
et al., 2009). C57BL/6 mice have deficient expression of
ART2.1 due to a premature stop codon in the Art2a
gene (Kanaitsuka et al., 1997), which may explain these
observations (Adriouch et al., 2001; Hong et al., 2009).
Alternatively, these differences may also be explained
by a known loss-of-function SNP present in C57BL/6, but
not BALB/c, P2X7 (see section VIII). Second, ART2.2 has
been reported on T cells, but not macrophages, from a
number of mouse strains (Okamoto et al., 1998;
Koch-Nolte et al., 1999; Hong et al., 2007). Moreover, bone
marrow-derived macrophages from BALB/c mice do not
constitutively express any ecto-ART subtypes; however,
ART2.1 is upregulated on these cells in response to
proinflammatory mediators (Hong et al., 2007). Despite
this, these macrophages remain unresponsive to NAD
when primed (Hong et al., 2009). Rather, NAD appears to
potentiate ATP-induced P2X7 activation in these cells
(Hong et al., 2009). Together, these results indicate that
ART2.2 is important for NAD-mediated P2X7 activation
and that different P2X7 signaling mechanisms operate in
lymphoid and myeloid leukocytes, at least in mice.
III. The Human P2X7 Receptor
Human P2X7 was first cloned from a human monocytic cDNA library (Rassendren et al., 1997) using
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information from the cloned rat P2X7 sequence. Several
pharmacological differences exist between human and
rodent P2X7, including varying EC50 values for agonists
ATP and BzATP (10- to 25-fold higher for humans) and
sensitivity to other compounds. The agonist profile for
human P2X7 is BzATP .. ATP . 2MeSATP . ATPgS
. . ADP (Gargett et al., 1997; Donnelly-Roberts et al.,
2009). Differences are also apparent in the electrophysiological profile between human and rat P2X7, with
faster deactivation observed with human P2X7 expressed in HEK-293 cells activated by either ATP or
BzATP (Rassendren et al., 1997). The C terminus was
responsible for this effect because a chimeric receptor
with human ectodomain and rat C terminus displayed an
increased deactivation time, similar to rat P2X7
(Rassendren et al., 1997). More recently, Roger and
colleagues (2008, 2010a) identified differences in the
intracellular regulation of human and rat P2X7 by
calmodulin. Rat P2X7 displays a Ca2+-calmodulin dependent facilitation of the ATP-induced inward current
via a C-terminal calmodulin binding site, whereas human
P2X7 only displays a smaller Ca2+-independent facilitation (Roger et al., 2010a).
IV. P2X7 Receptors of Other Mammalian Species
The P2X7 receptor has also been cloned from the guinea
pig, dog, and Rhesus macaque. Details of recombinant and
native P2X7 from these mammalian species are limited, but
nevertheless highlight the potential of these species for the
future study of P2X7-related diseases and in the mandatory
testing and evaluation of preclinical drugs targeting P2X7.
A. The Guinea Pig P2X7 Receptor
Guinea pig P2X7 was first cloned from a guinea pig
brain cDNA library (Fonfria et al., 2008). Unlike the
other cloned mammalian P2X7 receptors, guinea pig
P2X7 is 594 amino acids in length because of the absence
of a glutamic acid at position 77 (Fonfria et al., 2008). The
EC50 value for ATP for guinea pig was similar to that of
human P2X7, but in contrast to human (and rat) P2X7,
BzATP was a weak partial agonist of guinea pig P2X7
(Fonfria et al., 2008). Notably, BzATP-induced responses
were observed only in sucrose medium (Fonfria et al.,
2008). The capacity of other nucleotides and NAD to
activate this rodent P2X7 has not been assessed. Moreover,
the electrophysiological characteristics of recombinant
guinea pig P2X7 are yet to be reported, although P2X7mediated currents have been detected in guinea pig
myenteric neurons (Valdez-Morales et al., 2011). Further studies of native P2X7 within this species are
required before guinea pigs can serve as a model of
P2X7-related disorders and preclinical drug testing.
B. The Canine P2X7 Receptor
Canine P2X7 was first cloned from a dog heart cDNA
library from a nondisclosed breed (Roman et al., 2009).

EC50 values for both BzATP and ATP of canine P2X7
were similar to that of human P2X7; however, BzATP
was only a partial agonist of canine P2X7 (Roman
et al., 2009). In contrast, activation of P2X7 in canine
erythrocytes identified that ATP, relative to BzATP,
was a partial agonist of native canine P2X7 (Stevenson
et al., 2009). This finding is similar to that of native
human P2X7, in which ATP was also reported to be a
partial agonist relative to BzATP (Gargett et al., 1997).
The reasons for these differences between recombinant
and native canine P2X7 remain unknown but may
relate to the functional assays employed or the cell
types studied. The electrophysiological profile varies
between human and canine recombinant P2X7, with a
slower onset and decline in inward currents for canine
P2X7 than human P2X7 expressed in HEK-293 cells
activated by either ATP or BzATP (Roman et al., 2009).
The capacity of other nucleotides to activate recombinant canine P2X7 has not been assessed. However,
study of native P2X7 in canine erythrocytes demonstrates that 2MeSATP and ATPgS, but not ADP or
UTP, may also be (partial) agonists of canine P2X7
(Sluyter et al., 2007). NAD also failed to induce ethidium+
uptake into canine lymphocytes and monocytes (Stevenson
et al., 2009), suggesting that NAD is not an agonist of
canine P2X7.
Some attempts have been made to determine the
tissue distribution of P2X7 in dogs. Functional P2X7
has been reported in erythrocytes, T cells, B cells, and
monocytes (Sluyter et al., 2007; Stevenson et al., 2009;
Jalilian et al., 2012a), as well as in kidney epithelial
cells (Jalilian et al., 2012b). Of note, P2X7 activation
induces the release of interleukin (IL)-1b from canine
monocytes (Jalilian et al., 2012a) and whole blood
(Roman et al., 2009; Spildrejorde et al., 2014). Collectively, these studies support the potential use of dogs in
future studies of P2X7. In this regard, laboratories of
GlaxoSmithKline (GSK) and Pfizer have already used
dogs to assess the pharmacokinetics and bioavailability
of P2X7 antagonists, including 2-oxo-N-(phenylmethyl)-4imidazolidinecarboxamide analogs (Abberley et al., 2010)
and 2-(4-chloro-3-[3-(1-hydroxycycloheptyl)propanoyl]
phenyl)-4-[(2R)-2-hydroxy-3-methoxy-propyl]-1,2,4triazine-3,5-dione (CE-224,535) (Duplantier et al.,
2011), respectively. The pharmacokinetics and bioavailability of these compounds in dogs were similar
to that observed for monkeys (Abberley et al., 2010;
Duplantier et al., 2011) and thus potentially similar to
that of humans.
C. The Rhesus Macaque P2X7 Receptor
Rhesus macaque P2X7 was the first recombinant
P2X7 to be synthesized from a published sequence
rather than being generated via traditional cloning
techniques (Bradley et al., 2011b). Both BzATP and
ATP induce robust currents in cells transfected with
Rhesus macaque P2X7, with EC50 values similar to
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that of human P2X7 (Bradley et al., 2011b). The capacity
of other nucleotides or NAD to activate Rhesus macaque
P2X7 has not been assessed. In regard to the latter, it is
likely that NAD will also not activate Rhesus macaque
P2X7, because the ART2 ortholog appears to be absent in
primates (Haag et al., 1994). P2X7 protein is present in
the retinal neurons of the Rhesus macaque (Ishii et al.,
2003), but functional evidence and the tissue distribution
of native P2X7 within these animals are lacking. Collectively, this limits the potential utility of these nonhuman
primates as a model of P2X7-related diseases and preclinical testing of drugs targeting this receptor at this time.
V. Gating of the P2X7 Receptor Channel
The binding of agonist molecules to ligand-gated ion
channels transduces a signal to the channel gate, the
region of the protein involved in opening the channel
pore and allowing ionic flux to occur. Similar to other
P2X receptors, P2X7 receptors are trimeric in structure
(Nicke, 2008; Jiang et al., 2013) and contain three
intersubunit nucleotide binding sites with residues
from two individual monomers both contributing to the
binding site. Six helical transmembrane domains span
the membrane, and it is thought that the second
transmembrane domains (TM2) of each P2X7 monomer
form a physical gate to the flow of ions (reviewed in
Jiang et al., 2013). Structural data from P2X4 (Hattori
and Gouaux, 2012) suggest a rotation of the transmembrane domains after agonist binding opening the
channel pore. The external portion of TM2 has been
implicated as a channel gating domain; residues Ile332
to Val343 in P2X2 correspond to residues Val335 to
Leu346 in P2X7 (Li et al., 2008). Once the TM2
domains have moved, the channel pore is fully open
and conducts current, the directionality of this being
dictated by the membrane potential. After agonist
binding and gating rearrangements, monophasic or
biphasic currents can be measured by standard wholecell electrophysiology (Yan et al., 2008, 2011; Khadra
et al., 2013). Mono- and biphasic currents through
P2X7 channels are distinguished by the agonist concentration and whether the channel is “naive” to
agonist or not (Khadra et al., 2013). However, P2X7
gating is more complex than other ion channels
because of the secondary permeability pathway (see
section VI). Single channel recordings of P2X7 channels have also been used to investigate how this ion
channel operates. Markwardt and colleagues measured
a single channel conductance of 9–13 pS for P2X7 in
Xenopus laevis oocytes (Riedel et al., 2007a) and have
developed extensive kinetic models for the transitions
between open and closed states. These kinetic models
were recently extended to a 16-state Markov model,
taking into account both low-high affinity agonist binding
and sensitization/desensitization states (Khadra et al.,
2013).
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VI. Permeability of the P2X7 Receptor
P2X7 was originally identified as the P2Z receptor,
capable of permeabilizing cells after ATP addition.
This defining feature of P2X7 activation was thought to
be unique to this receptor for many years. However it is
now apparent that activation of other purinergic
receptors (P2X2, P2X4, P2X5, and P2X2/5), and indeed
other ligand-gated ion channels (N-methyl-D-aspartate
receptor and the transient receptor potential cation channel
subfamily A member 1 and subfamily V member 1) can
also permeabilize cells (Virginio et al., 1999; Chaumont
and Khakh, 2008; Chung et al., 2008; Thompson et al.,
2008; Banke et al., 2010; Compan et al., 2012b). Despite
these observations, it should be noted that P2X7 is the
only P2X receptor where this process is consistently
observed. The secondary pore pathway permits the
entry of normally impermeant organic cations such as
N-methyl-D-glucamine+, ethidium+, and YO-PRO-12+. Organic anions such as lucifer yellow and carboxyfluorescein
can also enter cells, although whether this involves the
same permeation pathway as for cations is unclear. In
addition to ion channels, the marine toxin maitotoxin
(Schilling et al., 1999) and a sustained elevation of
intracellular Ca2+ using the ionophore ionomycin (Faria
et al., 2009) can also induce the opening of a pore pathway permitting impermeant dye entry.
The search to understand the mechanism by which
P2X7 permits large cation/anion uptake is still ongoing, as
is the debate regarding whether this is an intrinsic
property of P2X7 or whether it requires at least one other
protein. Several studies have shown that the unique and
characteristic long C-terminal tail of P2X7 is crucial for
pore formation. Truncation of P2X7 abolishes dye uptake
without affecting ion channel currents (Surprenant et al.,
1996; Rassendren et al., 1997; Smart et al., 2003). Single
point mutations due to polymorphisms can also dramatically affect the dye uptake response (Gu et al., 2001;
Adriouch et al., 2002; Wiley et al., 2003). In addition,
there is reported to be some dependence on second
messenger pathways, including a role for Ca2+ (DonnellyRoberts et al., 2004; Faria et al., 2005). These studies and
others (reviewed in Rokic and Stojilkovic, 2013) have
attempted to dissect out ion channel and secondary pore
pathways. A breakthrough in mechanistic understanding
came with the identification of pannexin-1 as a secondary
protein involved in dye uptake (Pelegrin and Surprenant,
2006). However, there is now growing evidence suggesting that pannexin-1 cannot be the major pore pathway
used by P2X7. For example, no defect in ATP-mediated
YO-PRO-12+ uptake was observed in macrophages from
pannexin-1 knockout (KO) mice (Qu et al., 2011), siRNA
knockdown of pannexin-1 in mouse macrophages failed to
affect P2X7 responses (Alberto et al., 2013), and pharmacological blockade of pannexin-1 did not affect ATP-induced
dye uptake in transfected HEK-293 cells or human
monocytes (Bhaskaracharya et al., 2014).
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Electrophysiological recordings of P2X7 currents suggest that biphasic currents reflect pore dilation (Yan
et al., 2008; Khadra et al., 2013), and therefore a large
proportion of the inward current is via the secondary
permeability pathway. However, biphasic currents have
not been recorded under single channel recording conditions (Riedel et al., 2007b). Recently, Browne et al.
(2013) provided evidence for direct permeation of large
molecules through the P2X7 channel pore. By introducing
cysteine mutations into TM2, which lines the conductance
pathway of the P2X7 channel pore, the direct access of
methanethiosulfonate reagents to these residues after
ATP treatment was demonstrated. Inhibition of P2X7
ion channel currents using methanethiosulfonate
reagents also blocked fluorescent dye uptake (Browne
et al., 2013).
Given the importance of the secondary permeability
pathway in signaling events downstream of P2X7
activation (see section VII), it is necessary that a clear
understanding of this secondary pathway is established. Moreover, we must also consider the physiologic
relevance of this additional pore pathway allowing
influx/efflux of large molecules. Is this a mechanism for
cells to take up ATP or other molecules required for an
increased metabolic demand to respond to tissue injury
or inflammation? Is this a mechanism for ATP release
to drive further purinergic signaling? Or does this
pathway provide a way of secreting chemical transmitter molecules such as glutamate? Cervetto and
colleagues (2013a) recently demonstrated that glutamate efflux from P2X7-transfected HEK-293 cells was
dependent on the long C terminus of rat P2X7 and the
Cys-rich domain of the proximal C terminus, implicating the secondary pore pathway in efflux events.
VII. P2X7 Receptor-Dependent
Signaling Pathways
A number of cell type-specific signaling pathways
have been associated with P2X7 activation. These include
the activation of the caspase-1–containing inflammasome
NLRP3 and the subsequent processing and release of
proinflammatory interleukin-1 (IL-1) cytokines, as well as
the formation of reactive oxygen and nitrogen species and
the formation of phagolysosomes and subsequent killing of
intracellular pathogens (see Hewinson and Mackenzie,
2007; Miller et al., 2011; Di Virgilio, 2013). Here we will
review recent developments in established signaling
pathways and novel signaling pathways associated with
P2X7.
A. Cytokine Release
In addition to the secretion of leaderless cytokines
IL-1b (IL-1F2) and IL-18 (IL-1F4), P2X7 activation has
also been shown to induce release of IL-1a (IL-1F1)
(Pelegrin et al., 2008), IL-1 receptor antagonist (IL-1F3)
(Wilson et al., 2004, 2007; Glas et al., 2009) and IL-36a

(IL-1F6) (Martin et al., 2009). This places P2X7 as a
major physiologic regulator of secretion of the IL-1
family of cytokines. A recent comprehensive investigation into the mechanism underlying NLRP3 inflammasome activation and IL-1b secretion by diverse stimuli,
including P2X7, suggests K+ efflux is a common signal
activating the NLRP3 complex (Muñoz-Planillo et al.,
2013). Extracellular osmolarity and cell volume regulation
also plays a role in the activation of NLRP3 inflammasome (Compan et al., 2012a), highlighting that it is the
cellular microenvironment that is crucial for switching on
cytokine secretion.
B. Reactive Oxygen Species Formation
The generation of reactive oxygen species (ROS) after
ATP activation of P2X7 is now well established in
macrophages (Lenertz et al., 2009; Moore and MacKenzie,
2009), microglia (Apolloni et al., 2013; Bartlett et al.,
2013), submandibular gland cells (Seil et al., 2008),
and erythroid cells (Wang and Sluyter, 2013). Activation of NADPH oxidase 2 by P2X7 was a common
feature found in all cell types studied, although there is
evidence that ATP, possibly via P2X7 activation, can
also enhance mitochondrial reactive oxygen species
(Nakahira et al., 2011). One downstream consequence
of increased ROS generation in myeloid cells is the
activation of the NLRP3 inflammasome and IL-1b
secretion (reviewed in Gross et al., 2011; Tschopp, 2011).
However, in a more recent study, ROS were not found to
play a role in NLRP3 activation in bone marrow-derived
macrophages (Muñoz-Planillo et al., 2013). Rather, a reduction of the intracellular K+ concentration was required.
Despite this, there is evidence that K+ channel activity can
be positively modulated by ROS (Ichinari et al., 1996;
Avshalumov and Rice, 2003; Sesti et al., 2010), and it may
be that ROS are able to induce NLRP3 activation in some
cell types via this signaling process.
C. Protease Activation and Release
Activation of P2X7 receptors can also lead to a number
of membrane-related changes including membrane blebbing, microparticle and exosome release, multinucleated
cell formation, reversible phosphatidylserine exposure,
and the activation of membrane metalloproteases resulting in the shedding of cell-surface molecules (see Qu and
Dubyak, 2009; Wiley et al., 2011). Recent work has
identified additional cell surface molecules shed from
the cell surface or released after activation of P2X7.
This includes the chemokine CXCL16 (Pupovac et al.,
2013a), the adhesion molecule CD44 (Lin et al., 2012),
soluble amyloid precursor protein (Delarasse et al.,
2011), and the IL-6 receptor (Garbers et al., 2011), in
addition to CD62L (L-selectin), CD23 (the low-affinity
IgE receptor) (Gu et al., 1998), and CD27 (Moon et al.,
2006). Two metalloproteinases, ADAM10 and ADAM17,
are the main effector molecules associated with these
P2X7-mediated shedding events (Garbers et al., 2011;
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Pupovac et al., 2013a). Many physiologically relevant
substrates are cleaved by these proteases, and it will be
interesting to determine if P2X7 can induce cleavage of
all ADAM10/17 substrates or only a subset.
P2X7 activation can also induce the release of various
enzymes. Andrei and colleagues (2004) first identified
that ATP could induce lysosome exocytosis from human
monocytes and measured cathepsin D secretion as a
readout. It is now clear that lysosome secretion of
cathepsins is a P2X7-mediated pathway likely regulated
by increased intracellular Ca2+ concentrations. Cathepsins
B, D, L, and S are also secreted in this manner from
monocytes and macrophages (Lopez-Castejon et al.,
2010). P2X7 activation can also stimulate the release
of metalloprotease-9 (Gu and Wiley, 2006); however, the
specific release mechanism is yet to be ascertained.
Therefore, P2X7 can regulate several families of proteases,
namely caspases (Ferrari et al., 1999), as well as
cathepsins and matrix metalloproteinases.
D. Prostaglandin Release
Prostaglandin E2 (PGE2), thromboxane B2, and leukotriene B4 are prostanoids induced by P2X7 signaling in
murine macrophages (Barberà-Cremades et al., 2012).
Phospholipases mediate the hydrolysis of arachidonic
acid from various phospholipids, and P2X7 is known to
activate cytosolic phospholipase A2 (Andrei et al., 2004)
and Ca2+-insensitive phospholipase A2 isoforms (El
Ouaaliti et al., 2012), in addition to phospholipase D
(el-Moatassim and Dubyak, 1992). Arachidonic acid is
then a substrate for cyclooxygenase and prostaglandin
E synthases in the biosynthesis of PGE2. PGE2 plays
an important role in inflammation, fever, and pain,
and therefore is likely to be an important downstream
signaling pathway from P2X7 in vivo. Given the activation
of P2X7 by ATP in areas of tissue damage, this may place
P2X7 as a potential alternative anti-inflammatory target
to cyclooxygenase (Barberà-Cremades et al., 2012).
E. Glutamate Efflux
Early reports exist showing that P2X7 induces nonvesicular release of excitatory amino acids such as
glutamate and aspartate from murine astrocytes (Duan
et al., 2003; Fellin et al., 2006). This finding was recently
extended with the demonstration that P2X7 activation
could induce glutamate efflux from rat cortical nerve
terminals (Marcoli et al., 2008) and from HEK-293 cells
expressing recombinant rat P2X7 (Cervetto et al.,
2013a). Such contributions to extrasynaptic and/or
synaptic glutamate concentrations may alter neurotransmission and could contribute to changes in
neuroplasticity and behavior.
F. Transcription Activation
P2X7 can influence gene expression through activation of a variety of transcription factors. Several studies
have identified nuclear factor-kB p65 as a transcription
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factor regulated by P2X7 in microglia (Ferrari et al.,
1997) and osteoclasts (Korcok et al., 2004). In monocytes, P2X7 activation can also induce cAMP response
element-binding protein activation (Gavala et al., 2008)
and FosB/activating protein-1 (Gavala et al., 2010), and
in T cells, P2X7 activation can induce the translocation
of nuclear factor of activated T cells to the nucleus (Yip
et al., 2009). Therefore P2X7 may regulate gene expression in response to extracellular ATP, perhaps to
reprogram cellular metabolism in times of stress or to
switch on genes required for the inflammatory response.
G. Cell Proliferation
P2X7 is historically known for its ability of ATP to
induce cell death through apoptosis (Zanovello et al.,
1990; Chow et al., 1997; Ferrari et al., 1999). A role in
cell proliferation would seem to be at odds with this,
but evidence suggests that in certain cell types, activation of P2X7 is more likely involved with proliferation
than cell death. This may be due to expression of
particular splice variants (see section VIII), and this
aspect certainly warrants further investigation in T cells
and microglia. In T cells, release of autocrine ATP during
activation through the T-cell receptor activates P2X7 and
enhances secretion of the T-cell growth factor IL-2,
through stimulation of the nuclear factor of activated
T-cells transcription factor (Yip et al., 2009). Baricordi
and colleagues (1996) first suggested a role for P2X7
in mitogen-induced T-cell proliferation. This same group
subsequently went on to show that transfection of cell
lines with full-length P2X7 or a truncated splice variant of
this receptor increased cell proliferation, especially in the
absence of serum (Baricordi et al., 1999; Adinolfi et al.,
2005, 2010). In microglia, blocking P2X7 pharmacologically or overexpressing a pore-mutant (G345Y) to abolish
secondary permeability reduced the proliferative response
(Bianco et al., 2006; Monif et al., 2009). It will be interesting to determine if the trophic effect in microglia is
also due to transcriptional regulation of a growth factor.
H. Phagocytosis
A novel cellular signaling process associated with
P2X7 is the regulation of phagocytosis (Wiley and Gu,
2012), a process by which foreign particles or organisms are taken up into cells. Transfection of HEK-293
cells, which are not normally phagocytic cells, with
DNA encoding P2X7 introduces the ability to take up
1-mm latex beads or fluorescently labeled bacteria
(Gu et al., 2010). Gu and colleagues (2009, 2010, 2011,
2012) propose that P2X7 is acting as a scavenger receptor.
Typically, scavenger receptors, such as CD36, recognize
modified lipoproteins, such as low-density lipoproteins
(Endemann et al., 1993), and although it is noted that
P2X7 has a similar two transmembrane domain structure
to CD36 (Gu et al., 2011, 2012), whether P2X7 can
recognize such lipoproteins is not yet known. The ability of
P2X7-expressing cells to take up particles does not appear
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to require classic activation of the ion channel by
extracellular ATP. In fact, stimulation of the channel
with ATP switches off this phagocytic pathway (Gu et al.,
2010). This suggests that particle uptake does not require
classic signaling through the ion channel or the secondary
pore pathway, but may use a novel signaling pathway
due to association of P2X7 with the cytoskeleton (Gu
et al., 2009, 2010). This is an exciting development in
P2X7 cell biology, and further investigations may reveal
other ligands for this receptor.
I. Summary
In summary, P2X7 regulates ionic flux, protease activation, membrane events, and various secretion events. This is
a diverse series of signaling pathways commonly involved in inflammation. Because these signaling pathways are cell type specific, it is highly likely that each
cell type expressing P2X7 has a different complement of
downstream effectors. This information is critical as we
try to understand the role of P2X7 in disease and the
potential for this receptor as a therapeutic target.
VIII. Variants of the P2X7 Receptor
In the last 10 years, particular attention has been
drawn to the importance and contributions of P2X7
variants to the diversity of P2X7 receptor–mediated
responses in health and disease, bringing the purinergic field to a point where these variants can no longer
be ignored. In particular, these studies have highlighted the need for the consideration of variants in
current and future in vivo rodent studies and human
clinical trials. The two main causes of P2X7 variants,
P2X7 SNPs and splice isoforms, as well as their implications for rodent studies, will be discussed below. The
human P2X7 receptor will be discussed first because the
largest body of work has been done in this species.
A. P2X7 Single Nucleotide Polymorphisms
The human P2RX7 gene is highly polymorphic, with
over 1500 SNPs reported in the National Center for
Biotechnology Information (NCBI) SNP database (www.
ncbi.nlm.nih.gov/sites/entrez, accessed December 27,
2013). However, the majority of these SNPs are intronic,
with approximately 150 nonsynonymous (or missense)
SNPs reported in both this database and the Ensembl
Genome Browser (asia.ensembl.org/index.html, accessed
December 27, 2013). Of these nonsynonymous SNPs,
a small number have been investigated to date that lead
to altered human P2X7 function. A loss-of-function effect
has been reported for SNPs V76A, R117W, G150R,
E186K, L191P, R276H, R307Q, T357S, E496A, and
I568N (Gu et al., 2001, 2004; Wiley et al., 2003; Shemon
et al., 2006; Roger et al., 2010b; Stokes et al., 2010).
Because of the absence of frequency data it is not clear
whether R117W, E186K, or L191P represent SNPs or
mutations. Investigations into the underlying mechanisms

behind the loss-of-function effect of individual SNPs
have revealed differences depending on the site of the
mutations. Residue 307, originally thought to contribute
to ATP binding (Gu et al., 2004), may instead be involved in hydrogen bonding and salt bridge structures
in the P2X7 ectodomain (Jiang et al., 2013). Residue 568
lies within a trafficking motif, and mutant 568N-P2X7
receptors do not efficiently traffic to the cell membrane
(Wiley et al., 2003). It is currently unclear how V76A,
R117W, G150R, L191P, R276H, and E496A mutations
cause a loss-of-function effect. SNPs in regulatory and
intronic regions have also been identified, including
the upstream promoter region (2762; rs2393799) (Li
et al., 2002), an intronic splicing site at the exon1/
intron1 boundary (rs35933842) (Skarratt et al., 2005),
and the 39-untranslated region affecting a microRNA
binding site (rs1653625) (Rahman et al., 2010). However, only rs35933842 has been associated with a lossof-function effect.
A gain-of-function effect has been reported for three
SNPs: H155Y, H270R, and A348T (Cabrini et al., 2005;
Stokes et al., 2010). The underlying mechanisms behind
these gain-of-function effects have not been established.
There is some evidence to suggest that the amino acid
variation at 155 increases cell surface expression of
P2X7 (Bradley et al., 2011a); however, this was not
observed in the initial report of this SNP (Cabrini et al.,
2005). One of the most interesting SNPs in human
P2RX7 is Q460R in the C terminus. In isolation this
mutation does little to the functional response, but our
investigations revealed coinheritance with gain-of-function
SNPs in a particular haplotype (Stokes et al., 2010),
perhaps explaining the association of this SNP with
various disorders, including bipolar disorder (Barden
et al., 2006), depression (Lucae et al., 2006), and Sjogren’s
syndrome (Lester et al., 2013).
In the last 5 years many studies have investigated
the association of SNPs in P2RX7 with a number of
different diseases. Some studies have used individual
key SNPs such as E496A or Q460R, whereas others
have used a more informative 12 SNP approach. Lossof-function haplotypes have been linked to susceptibility to extrapulmonary tuberculosis infection (Fernando
et al., 2007), enhanced bone mineral density loss in
postmenopausal women (Gartland et al., 2012; Jorgensen
et al., 2012), and an increased risk of age-related
macular degeneration due to reduced phagocytosis of
cellular debris (Gu et al., 2013). Inheritance of E496A
has been linked to a reduced risk of ischemic stroke
and ischemic heart disease (Gidlof et al., 2012). The
gain-of-function A348T SNP is protective for Toxoplasmosis gondii infection (Jamieson et al., 2010) and
is found at an increased frequency in Arabic patients
with rheumatoid arthritis (Al-Shukaili et al., 2011)
and patients with major depressive disorder (Lucae
et al., 2006). Q460R, which is in linkage disequilibrium
with A348T, was found to be increased in patients with
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Sjogren’s syndrome and was linked to increased seropositive disease (Lester et al., 2013).
In summary, gain-of-function haplotypes of human
P2X7 may protect against infection and premature bone
loss, but may increase the risk of developing certain
inflammatory and psychiatric disorders. On the converse,
carrying loss-of-function haplotypes of P2X7 may protect
against inflammatory disorders, such as heart disease,
but may increase susceptibility to some infections.
A number of SNPs have similarly been reported in
the murine P2RX7 gene region, with a survey of the
NCBI SNP database revealing .1700 SNPs (accessed
December 27, 2013). The majority of these SNPs are
intronic. With the Ensembl Genome Browser (accessed
December 27, 2013), 34 SNPs were revealed to be present
in the coding region of the full-length murine P2RX7
gene, 10 of which are nonsynonymous (Fig. 1).
Of the nonsynonymous SNPs reported for murine
P2X7 in the NCBI SNP database and the Ensembl
Genome Browser, only the P451L SNP has been characterized. This naturally occurring mutation leads to the
replacement of the proline residue at position 451 by a
leucine residue in the cytoplasmic tail of murine P2X7
(Adriouch et al., 2002). The distribution of the allelic
versions of this SNP in different mouse strains is outlined
in Fig. 2. The P451L SNP was originally identified based
on studies of P2X7 function in T cells from different strains
of mice, whereby T cells from BALB/c mice (451P) had
significantly higher sensitivity to ATP than those from

Fig. 1. Nonsynonymous SNPs reported in the coding region of the
murine P2RX7 gene. SNP, SNP ID, and alleles are as follows: S6N,
rs227977285, and G/A; V32I, rs229167308, and G/A; E70Q, rs238213067,
and G/C; G113D, rs37541158, and G/A; T117M, rs238065774, and C/T;
R270Q, rs220799687, and G/A; P396R, rs37237164, and C/G; P451L,
rs48804829, and C/T; R486H, rs37867325, and G/A; H514R, rs36331015,
and A/G. Yellow and red circles refer to functionally characterized and
noncharacterized SNPs, respectively. SNPs were identified using
Ensembl Genome Browser (asia.ensembl.org/index.html, accessed December 27, 2013).
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Fig. 2. Allelic versions of the loss-of-function P2X7 P451L SNP in different
mouse strains (based on data from Adriouch et al., 2002; Sorge et al., 2012;
Syberg et al., 2012). The 451P allele is also observed in rats and humans.
Strains in italics are wild mouse strains. NZW, New Zealand White; NOD,
nonobese diabetic.

C57BL/6 mice (451L) (Adriouch et al., 2002). By transfecting HEK-293 cells with either of the two variants (451P
or 451L), it was demonstrated that P2X7 channel and pore
function were markedly reduced in cells expressing the
mutated 451L allele. This was later confirmed in another
study, in which HEK-293 cells expressing 451L had
reduced cation dye uptake and Ca2+ flux compared with
cells expressing 451P (Young et al., 2006). However,
451L was not found to be associated with reduced surface
protein expression or maximum agonist-induced currents
in this latter study. In contrast, human astrocytoma
1321N1 cells expressing 451L are reported to have fully
functional P2X7, with a similar pharmacological profile
to those expressing 451P (Donnelly-Roberts et al., 2009).
Differences in murine P2X7 function encoded by the
451P and 451L alleles are further supported by two
additional studies with BALB/c and C57BL/6 mice,
respectively. First, thymocytes from C57BL/6 mice
display significantly impaired P2X7-induced cell death
compared with those from BALB/c thymocytes (Le
Stunff et al., 2004). In contrast, P2X7-induced phospholipase D stimulation was similar in thymocytes
from both strains (Le Stunff et al., 2004). This suggests
that P2X7-induced cell death and phospholipase D
stimulation are controlled through distinct domains of
P2X7. Second, astrocytes from C57BL/6 mice have attenuated ATP-induced pannexin-1 currents, ATP release, and
intracellular Ca2+ waves compared with astrocytes from
BALB/c mice, all of which were thought to be mediated by
P2X7 (Suadicani et al., 2009). Of note, using a Src inhibitor
and electrophysiological, biochemical, and fluorescence
imaging techniques, this same study also provided
evidence that P451L is located within the SH3 domain, a
Src tyrosine kinase-binding site. This further supports the
potential influence of this SNP on domain structure and
function of the murine P2X7 receptor.
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The P451L SNP has been correlated with disease in
two studies. First, genome-wide linkage analysis studies
have found an association between the P451L SNP and
neuropathic pain in mice (Sorge et al., 2012). In this
study, mice from a number of different strains expressing the 451L allele showed less mechanical allodynia, a
symptom of neuropathic pain, after spared nerve injury
compared with those with the 451P allele. Second, an
association between the P451L SNP and bone phenotype has been reported (Syberg et al., 2012). Strains
with the 451L allele (C57BL/6 and DBA/2J) had weaker
femurs, lower amounts of the bone resorption marker
C-telopeptide collagen, and lower bone mineral densities compared with those strains with the 451P allele
(BALB/cJ and 129X1/SvJ). However, the cellular bases
for these differences were not established, whereas
other measured bone parameters were not associated
with the P451L SNP.
In addition to the naturally occurring P451L SNP,
nonsynonymous mutations have also been identified
in murine cell lines. For example, L11F, T221A, and
T283M mutations have been found in P2X7 cloned
from the NTW8 microglial cell line (Chessell et al.,
1998; Young et al., 2006). These mutations have been
associated with reduced function in this cloned receptor compared with the function of recombinant
P2X7 cloned from a C57BL/6 mouse (Adriouch et al.,
2002). By introducing point mutations, the T283M
SNP, but not L11F or T221A SNPs, was found to be
responsible for this low P2X7 function, with expression
of the 283M variant leading to both reduced channel
and pore activity (Young et al., 2006). In comparison,
the 283T allele is present in P2X7 sequences from other
mouse strains, as well as the rat and human sequences.
Thus, the T283M mutation may be specific to the NTW8
cell line or a result of cloning.
Further survey of the NCBI SNP database and
Ensembl Genome Browser (both accessed December 27,
2013) reveals few nonsynonymous SNPs in the coding
region of the other cloned mammalian P2X7 receptors.
Nonsynonymous SNPs in the rat or guinea pig P2RX7
gene have not been reported. Two nonsynonymous SNPs,
L103F and P452S, have been reported in the canine
P2RX7 gene. In the other cloned mammalian P2X7
receptors, a phenylalanine residue resides at amino acid
position 103. Thus, it is likely that 103F may also represent the more common variant in dogs and that the
SNP at this position may be more accurately defined as
F103L rather than the reported L103F. Nevertheless the
cloned canine P2X7, which contains a leucine residue at
amino acid position 103, forms a functional receptor
(Roman et al., 2009), although its relative effect compared
with canine P2X7 containing residue 103F remains unknown. The P452S SNP in the canine P2RX7 gene is
located at the equivalent position as the partial loss of
function SNP, P451L, of the murine P2RX7 gene. The
functional effect of this canine SNP remains unknown.

Finally, one nonsynonymous SNP, I75M, has been
reported in the Rhesus macaque P2RX7 gene. An
isoleucine residue is found at this amino acid position in
each of the other cloned mammalian P2X7 receptors,
and the functional effect of a methionine at this position
remains to be determined.
B. P2X7 Splice Isoforms
Alternative splicing is a process that enables one gene
to produce multiple protein isoforms, with a number of
alternative P2X7 splice variants identified for the human
and rodent receptor to date. In humans, seven naturally
occurring splice variants were initially reported and
termed P2X7B to P2X7H (Cheewatrakoolpong et al.,
2005), with P2X7A referring to the original full-length
595 amino acid protein (Rassendren et al., 1997). These
include truncated variants that have an alternate short
C terminus (P2X7B, C, E, and G), variants that lack
exons responsible for coding parts of the extracellular
domain (P2X7C–F) and variants that have additional
exons, thought to result in P2X7 protein lacking the first
transmembrane domain (P2X7G and H) (see Sluyter and
Stokes, 2011). An additional two naturally occurring
splice variants have been identified in humans, termed
P2X7I and P2X7J (Feng et al., 2006). P2X7I codes for
a null allele and is a result of SNP rs35933842 (Skarratt
et al., 2005), whereas P2X7J is another truncated variant
(Feng et al., 2006). These ten variants of human P2X7
differ in distribution, functional characteristics, and
predicted physiologic roles. Of these, P2X7B is the best
studied and is able to form functional channels but not
the large pores that are often associated with inflammation and cell death (Adinolfi et al., 2010). P2X7J is
similarly unable to form pores and also displays reduced
ligand-binding ability and channel function and oligomerizes with P2X7A to form nonfunctional P2X7 heterotrimers (Feng et al., 2006).
Naturally occurring P2X7 splice variants have also
been identified in rodents. The first reported, originally
termed P2X7(K) (Nicke et al., 2009) or P2X7K by
others (Masin et al., 2012), results from a novel exon 1
in the rodent P2RX7 gene. This leads to a receptor with
an alternate amino-terminal and first transmembrane
domain (Nicke et al., 2009). In contrast to the human
P2X7 variants mentioned above, P2X7K is a fully
functional variant, with an 8-fold higher sensitivity
to P2X7 agonists, slower deactivation, and increased
propensity to form P2X7 pores compared with P2X7A.
Furthermore, it was recently reported that this variant is
sensitive to activation by extracellular NAD, whereas
P2X7A is not (Schwarz et al., 2012). This is the first
report suggesting that NAD is unable to activate P2X7A,
which complicates the interpretation of earlier NAD
studies. In this study, T cells were found to preferentially
express P2X7K, whereas macrophages preferentially
express P2X7A. This may account for differences in
P2X7 signaling between these cell types in rodents (Hong
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et al., 2009; Xu et al., 2012) and suggests that P2X7
variants may mediate the differential sensitivity of
macrophages and lymphocytes to NAD. However, the
relative contribution of different P2X7 splice variants
on NAD-mediated P2X7 activation in other cell types,
such as astrocytes, has not been investigated. To the
best of our knowledge, a similar variant to P2X7K has
not been described in humans.
C-terminal truncated P2X7 variants have also been
identified in mice (Masin et al., 2012). These variants,
termed P2X7 13B and P2X7 13C, are encoded by genes
with alternative exon 13s, resulting in truncated or
alternate short C termini, respectively. P2X7 13B was
detected in all tissues tested, with strongest expression
in the brain, salivary glands, and spleen, whereas
P2X7 13C was present in the brain, lungs, and salivary
glands. When expressed in HEK-293 cells, both variants
displayed low cell surface expression and channel function and no pore formation. This low cell surface expression of P2X7 13B was due to inefficient trafficking
to the cell surface and, similar to the human variant
P2X7J (Feng et al., 2006), appeared to inhibit the function
of full-length P2X7 through hetero-oligomerization (Masin
et al., 2012). However, equivalent variants of human
P2X7B-J are yet to be reported in rodents. Furthermore,
the influence of these variants on P2X7 in vivo or even
native P2X7 on primary cells has not been widely
examined, and this may be a confounder in preclinical
studies in rodents, particularly if the sensitivity of
these variants to P2X7 antagonists varies.
C. P2X7 Variants in P2X7 Knockout Mice
There are currently two strains of P2X7 KO mice
available: the GSK line generated by Chessell et al.
(2005) (see also Sim et al., 2004) and the Pfizer line
generated by Solle et al. (2001). The GSK KO strain
was generated by inserting a lacZ transgene and neomycin cassette into exon 1, whereas the Pfizer KO was
generated by inserting a neomycin cassette into exon 13,
replacing part of the C terminus of the receptor. These
models have been extensively used for demonstrating
P2X7 involvement in inflammatory and neuropathic pain
(GSK KO), cytokine production, inflammation, bone
formation, and a number of disorders (Pfizer KO) (see
Volonté et al., 2012). However recent evidence, coinciding with the discovery of P2X7 splice variants,
indicates that these mice may not be true knockouts.
First, molecular and biochemical analyses indicated
that the widely expressed P2X7K splice variant discussed above escaped deletion in the GSK KO, with
highest expression in the spleen (Nicke et al., 2009).
This is likely because of the fact that exon 1 of the
P2RX7 gene was targeted in the generation of this KO
strain, whereas the P2X7K variant encodes a novel exon
1. Although P2X7 activity is absent in macrophages and
dendritic cells from this KO strain, T cells displayed
higher levels of P2X7 activity than that of control mice
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(Taylor et al., 2009a). Second, molecular and biochemical analyses indicated that P2X7 13B and 13C
C-terminal truncated variants, as well as a C-terminal
truncated hybrid variant containing a short sequence
of the targeting vector used to disrupt exon 13 of the
P2RX7 gene, escaped deletion in the Pfizer KO mouse
(Masin et al., 2012). However, unlike T cells from the
P2X7K-expressing GSK KO, those from the Pfizer KO
have reduced receptor function (Taylor et al., 2009a).
The tissue-specific expression of functional P2X7 in
these KO strains may explain the controversial staining of P2X7 in brain tissue from KO animals, which is
identical to that of wild-type (WT) littermates (Sim
et al., 2004; Sánchez-Nogueiro et al., 2005). In these
studies, P2X7 antibodies may be detecting splice variants,
which have escaped deletion, rather than P2X7-like
proteins with similar immunogenicity or other proteins
through nonspecific staining. In addition, these variants
may explain some of the phenotypic and functional
differences observed between these two KO strains (Fig.
3). Although P2X7 variants have escaped deletion in
both the GSK and Pfizer KOs, overall evidence indicates
that the P2X7A variant has been knocked out in both
strains. Despite this, caution needs to be undertaken
when interpreting results of in vivo studies that use
these KO mice.
IX. Modulators of P2X7 Receptor Activation
There are a number of P2X7 antagonists commercially available, all of which vary in terms of chemical
structure, mode of antagonism, specificity, and species
selectivity. The first generation of compounds available
that was capable of antagonizing P2X7 were generally
nonspecific, with many also capable of inhibiting other
P2X and in some cases P2Y receptors or other molecules
(see Gever et al., 2006). These early antagonists include
Reactive Blue 2, which was first used in the 1970s (Kerr
and Krantis, 1979); suramin and Brilliant Blue G (BBG),
which were first used in the 1980s (Dunn and
Blakeley, 1988; Soltoff et al., 1989); and pyridoxal
phosphate-6-azophenyl-2-4-disulfonic acid (PPADS),
periodate-oxidized ATP (oATP), and 1-[N,O-bis(5isoquinolinesulfonyl)-N-methyl-l-tyrosyl]-4-phenylpiperazine
(KN-62), which were first used in the 1990s (Lambrecht
et al., 1992; Murgia et al., 1993; Gargett and Wiley,
1997). Following on from their identification as P2X7
antagonists, structural modifications of these compounds were carried out in an attempt to improve their
properties and specificity (see Romagnoli et al., 2008;
Jiang, 2012). For example, MRS 2540 is based upon the
structure of KN-62, and exhibits enhanced potency at
both human and rodent P2X7 (Lee et al., 2008a; Hu
et al., 2010). Of the earlier compounds, BBG remains one
of the most useful. This compound is generally considered a specific P2X7 antagonist, blocking rat P2X7 in the
nanomolar compared with micromolar range or not at all
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Fig 3. Phenotypic and functional differences between GlaxoSmithKline (GSK) and Pfizer knockout (KO) mice compared with wild-type (WT)
counterparts. Differences in P2X7 isoforms expressed, bone phenotype (mineral density, volume, and thickness), P2X7-mediated responses in T cells
(pore formation, nucleotide-induced CD62L shedding, phosphatidylserine exposure, and cell death), and experimental autoimmune encephalomyelitis
(EAE) between P2X7 KO mice generated by GSK and Pfizer compared with WT. a(Solle et al., 2001; Sim et al., 2004; Nicke et al., 2009; Masin et al.,
2012); b(Gartland et al., 2003; Ke et al., 2003); c(Labasi et al., 2002; Taylor et al., 2008, 2009a); d(Chen and Brosnan, 2006; Sharp et al., 2008).

for other rat P2X receptors (P2X1, P2X2, P2X3, P2X2/3,
P2X4, and P2X1/5) (Jiang et al., 2000). More recent data
indicate that BBG also blocks pannexin 1 (Qiu and Dahl,
2009), complicating its use as a P2X7 antagonist. oATP
is also widely used to antagonize P2X7, but has also
been shown to inhibit other P2X receptors (including
P2X2 and P2X3) (Evans et al., 1995) and attenuate proinflammatory signaling through P2 receptor–independent
mechanisms (Beigi et al., 2003). However, the ability of
oATP to bind irreversibly to P2X7 via covalent modification of the receptor (Murgia et al., 1993) makes this
antagonist an attractive blocker of P2X7 in vivo. Likewise,
PPADS, which can also bind irreversibly to P2X receptors
(Nicke et al., 1998), also remains an attractive blocker of
P2X7 in vivo.
In the last two decades, a second generation of more
specific antagonists has been developed (see Friedle
et al., 2010; Bhattacharya et al., 2011; Jiang, 2012).
This has been aided by high-throughput screening of
large chemical libraries and has largely occurred alongside
reports indicating important roles for P2X7 in pain and
inflammation (Romagnoli et al., 2008). These newer druglike antagonists are particularly important for the
purinergic field, because the first generation of antagonists was generally designed for in vitro, rather than
therapeutic, use. Furthermore, many of the original
antagonists are subject to degradation when used in
vivo or are predicted to have poor pharmacokinetics
(Friedle et al., 2010; Jiang, 2012), problems avoided by
many of the second generation P2X7 antagonists. Second
generation P2X7 antagonists that have been characterized
include the tetrazole/triazole-based compounds 3-[[5-

(2,3-dichlorophenyl)-1H-tetrazol-1-yl]methyl]pyridine
(A438079) (Nelson et al., 2006) and 1-(2,3-dichlorophenyl)-N-[[2-(2-pyridinyloxy)phenyl]methyl]-1H-tetrazol5-amine (A839977) (Honore et al., 2009), the adamantane
amides N-[2-[[2-[(2-hydroxyethyl)amino]ethyl]amino]5-quinolinyl]-2-tricyclo[3.3.1.13,7]dec-1-ylacetamide
(AZ10606120) (Michel et al., 2007), and N-(adamantan1-ylmethyl)-5-[(3R-amino-pyrrolidin-1-yl)methyl]-2chloro-benzamide (AACBA; also known as GSK314181)
(Broom et al., 2008), the cyanoguanidine derivative
N-(1-([(cyanoimino)(5-quinolinylamino) methyl] amino)2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide
(A740003) (Honore et al., 2006), the cyclic imide 3-[1[[(39-nitro[1,19-biphenyl]-4-yl)oxy]methyl]-3-(4-pyridinyl)
propyl]-2,4-thiazolidinedione (AZ11645373) (Stokes
et al., 2006), and the nicotinamide derivative N-([4-(4phenyl-piperazin-1-yl]tetrahydro-2H-pyran-4-yl)-methyl)2-(phenyl-thio) nicotinamide (JNJ-47965567) (Letavic
et al., 2013). The concentration responses of some of these
specific antagonists (including A438079 and AZ11645373)
have been determined at native murine P2X7 receptors
(Bartlett et al., 2013; Pupovac et al., 2013b), which is
useful for their in vivo application. However, despite the
availability of these newer P2X7 antagonists, many in vivo
studies still use first generation antagonists (see section
X). Moreover, there are a number of additional potential
antagonists identified that have yet to be fully characterized (Donnelly-Roberts and Jarvis, 2007).
One factor confounding pharmacological studies of
P2X7 is the differential activity of P2X7 antagonists at
receptors from different species (Table 2). For example,
KN-62 at nanomolar concentrations potently inhibits

651

P2X7 Antagonists in Models of Disease

all cloned mammalian P2X7 receptors, except rat,
when expressed in HEK-293 cells (Fonfria et al., 2008;
Donnelly-Roberts et al., 2009; Roman et al., 2009;
Bradley et al., 2011b). In comparison, the commonly
used in vivo P2X7 antagonist BBG is at least a 3-fold
more potent antagonist of rat, murine, canine, or guinea
pig P2X7 than human P2X7 (Fonfria et al., 2008;
Donnelly-Roberts et al., 2009; Roman et al., 2009).
Although these and similar studies reveal important
insights into the specificity and selectivity of P2X7
antagonists, many are limited to examining recombinant P2X7 expressed in mammalian cells. It is unknown
if the functional characteristics of P2X7 in these studies
deviate from that of native P2X7 and, if so, to what
degree. In addition, in vitro pharmacological results,
and in particular IC50 values, are highly dependent on a
number of factors. These include the assay (e.g., whether
studying channel opening or pore formation), assay buffer
(e.g., presence of divalent cations and bovine serum
albumin can be inhibitory), host cell or cell type, agonist
concentration, assay temperature, and antagonist mechanism of action (e.g., competitive or noncompetitive, reversible or irreversible, orthosteric or allosteric) (Hibell
et al., 2001; Donnelly-Roberts and Jarvis, 2007). Of the
antagonists listed in Table 2, PPADS, BBG, Reactive
Blue, KN-62, and AZ10606120 are noncompetitive inhibitors of P2X7 (Jiang et al., 2000; Hibell et al., 2001; Honore
et al., 2006; Felix et al., 2012). In contrast, A438079,
A740003, and AZ11645373 are competitive inhibitors of
P2X7 (Alcaraz et al., 2003; Nelson et al., 2006; Yan et al.,
2011), whereas the mechanism of action of JNJ-47965567
remains to be determined. Collectively, all of the above
have implications for direct pharmacological comparisons
between in vitro studies but, more importantly, for the use
of these antagonists in vivo. In this regard, the in vivo

cellular environment may result in drastically different
outcomes of P2X7 antagonists to those outcomes observed
in vitro. In addition, an efficacious antagonist in an in vivo
rodent model may not translate to a human therapeutic
because of the differential activity of P2X7 antagonists at
receptors from different species. Furthermore, differences
between individuals may highly impact upon the efficacy
of these compounds. Thus a number of factors need to be
considered when using P2X7 antagonists in vivo.
In addition to the above experimental differences,
variations in amino acid homology in the ectodomain or
presumed antagonist binding site between species may
be one explanation for the differential activity of P2X7
agonists and antagonists at receptors from different
species (Young et al., 2007; Michel et al., 2008). For
example, one ectodomain residue (N284D) accounts
for the 10-fold difference in ATP sensitivity between
rat and mouse P2X7 (Young et al., 2007), whereas two
other ectodomain residues (F95L and R126G) are important for the different antagonist effects of KN-62
and PPADS, respectively, at the human and rat receptor
(Michel et al., 2008). Furthermore, P2X7 variants,
including SNPs and splice isoforms, are likely to play
a role in the differential activity of these compounds
both between and within species. For example, N-[(2,4dichlorophenyl)methyl]-1-methyl-5-oxo-l-prolinamide
(GSK1370319A) has an almost 7-fold higher IC50 value
for ATP-induced IL-1b in human blood cultures from
individuals with the A348T gain-of-function SNP than
those from individuals with the E496A loss-of-function
SNP (McHugh et al., 2012). Thus, given that human
P2X7 is highly polymorphic (see section VIII), this has
ramifications for the future use of P2X7 antagonists in
treating human disorders. In particular, a need for
prospective genotyping and tailor-made drug regimens

TABLE 2
Antagonist profiles of mammalian P2X7
IC50
Species
PPADS

BBG

Reactive
Blue

KN62

A438079 A740003 AZ10606120 AZ11645373

JNJ47965567

References

mM

Human

1.2

1.9

5.4

0.2

0.9

0.09

0.003

0.05

0.005

N.D.

N.D.

N.D.

0.1

0.3

N.D.

0.004

0.02

0.003

N.D.

0.05

N.D.

0.01

3.9

N.D.

0.06

0.04

0.005

Rat

1.2

0.6

0.1

0.1

0.03

Mouse
(BALB/c)

4.9

0.2

21

0.2

0.6

0.7

0.6a

1.6a

0.03a

0.5

18

0.6

0.6

1.7

0.6a

1.6a

0.03a

0.02

N.D.

0.1

N.D.

N.D.

N.D.

1.2

N.D.

Rhesus
macque
Dog

Mouse
(C57BL/6)
Guinea pig

40
0.2

N.D., not determined.
a
Mouse strain not disclosed.

2.8 .100

.20

0.063

Donnelly-Roberts et al., 2009;
Michel et al., 2009; Roman et al.,
2009; Bhattacharya et al., 2013
Bradley et al., 2011b; Bhattacharya
et al., 2013
Michel et al., 2009; Roman et al.,
2009; Bhattacharya et al., 2013
Donnelly-Roberts et al., 2009; Michel
et al., 2009; Bhattacharya et al.,
2013
Donnelly-Roberts et al., 2009; Michel
et al., 2009; Bhattacharya et al.,
2013
Donnelly-Roberts et al., 2009;
Michel et al., 2009; Bhattacharya
et al., 2013
Fonfria et al., 2008; Michel
et al., 2009
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is highlighted. Likewise, P2X7 variants also need to
be considered when investigating the pharmacological
blockade of P2X7 in rodents, with many studies to date
overlooking the existence of such variants.
In addition to the nonspecific and specific P2X7
antagonists listed above, a number of other compounds
have been shown to block P2X7 activation, many with
IC50 values in the micromolar range (Table 3). Naturally
derived compounds such as the traditional Chinese herb
emodin (Liu et al., 2010; Jelassi et al., 2013; Zhu et al.,
2014), the plant-derived alkaloids berberine and sanguinine
(Shemon et al., 2004), niphatoxin C, sytlissadine A and
sytlissadine B from the marine sponge (Buchanan et al.,
2007a,b), and the estrogen hormone 17b-estradiol (CarioToumaniantz et al., 1998) can each block P2X7. The effects
of other naturally derived compounds on P2X7 such as
chelerythrine and colchicine are discussed below. Moreover,
a number of enzyme inhibitors can block P2X7. Inhibitors
of the Ca2+/calmodulin-dependent protein kinase (KN-62)
(Gargett and Wiley, 1997), protein kinase C [chelerythrine
and Ro 31-8220 (2-[1-(3-(amidinothio) propyl)-1H-indol3-yl]-3-(1-methylindol-3-yl) maleimide methanesulfonate)] (Shemon et al., 2004, 2007), mitogen-activated
protein kinases [SB 203580 4-(4-fluorophenyl)-2-(4methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole] and
SB 202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)5-(4-pyridyl)-1H-imidazole]] (Michel et al., 2006), a vascular endothelial growth factor receptor tyrosine kinase
(Compound P [N-[4-(1-methylethyl)phenyl]-4-[2-(3-pyridinyl)
ethyl]-1-phthala-zinamine]) (Shemon et al., 2008),
and phospholipase D (CAY10593 [N-[2-[4-(5-chloro-2,3dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]-1methylethyl]-2-naphthalenecarboxamide], CAY10594

[N-[2-(4-oxo-1-phenyl-1, 3, 8-triazaspiro[4, 5]dec-8-yl)
ethyl]-2-naphthalenecarboxamide], and halopemide)
(Pupovac et al., 2013b) can each directly block P2X7.
In this regard, studies investigating signaling pathways downstream of P2X7 activation through the use
of enzyme inhibitors need to ensure that such compounds do not directly impair P2X7. A number of
therapeutic drugs can also impair P2X7 activation.
The antipsychotic drugs, prochlorperazine and trifluoperazine and to a lesser extent triflupromoazine
can each impair human, but not rodent, P2X7 channel
and pore activation (Hempel et al., 2013). Colchicine,
a drug used to treat gout and familial Mediterranean
fever, can inhibit P2X7 pore but not channel activation (Marques-da-Silva et al., 2011). More recently,
probenecid, which is used occasionally in the treatment of gout, has been found to block both the human
P2X7 channel and pore (Bhaskaracharya et al., 2014).
Thus, again caution needs to be made when assigning
inhibitory actions of these drugs in both in vitro and
in vivo studies. Furthermore, the possibility remains
that the therapeutic action or unwanted side effects of
such drugs may be due, in part, to P2X7 blockade.
In addition to chemical compounds, P2X7 can be
blocked by various cations (Jiang, 2009). In particular,
the divalent cations Ca2+ and Mg2+, at concentrations
found in vivo, can inhibit P2X7 activation in vitro
(Surprenant et al., 1996; Chessell et al., 1998). The
ability of these divalent cations to impair P2X7 is
attributed to the ability of these cations to chelate the
free acid form of ATP (or ATP42), the presumed form of
ATP responsible for P2X7 activation (Cockcroft and
Gomperts, 1979; Li et al., 2013). However, evidence

TABLE 3
Natural and other pharmacological compounds that impair P2X7 activation
Compound

Species

IC50

References

mM

Natural compounds
Emodin
Berberine
Sanginine
Niphatoxin C
Sytlissadine A
Sytlissadine B
17b-Estradiol
Enzyme inhibitors
KN-62
Chelerythrine
Ro 31-8220
Compound P
SB-203580
SB-202190
CAY10593
CAY10594
Halopemide
Therapeutic drugs
Colchicine
Prochlorperazine
Trifluoperazine
Triflupromoazine
Probenecid
N.D., not determined.

Human, rat
Human
Human
Human
Human
Human
Human

3, 1
N.D.
N.D.
.10
1
2
3

Liu et al., 2010; Jelassi et al., 2013; Zhu et al., 2014
Shemon et al., 2004
Shemon et al., 2004
Buchanan et al., 2007b
Buchanan et al., 2007a
Buchanan et al., 2007a
Cario-Toumaniantz et al., 1998

Human, mouse
Human
Human
Human, dog
Human
Human
Human
Human
Human

0.1, 1
6
N.D.
5, N.D.
0.4–4
0.6–16
2
.10
.10

Gargett and Wiley, 1997; Donnelly-Roberts et al., 2009
Shemon et al., 2004
Shemon et al., 2007
Shemon et al., 2008
Michel et al., 2006
Michel et al., 2006
Pupovac et al., 2013b
Pupovac et al., 2013b
Pupovac et al., 2013b

Human, mouse, rat
Human
Human
Human
Human

N.D.
1
2
.50
200

Marques-da-Silva et al., 2011
Hempel et al., 2013
Hempel et al., 2013
Hempel et al., 2013
Bhaskaracharya et al., 2014
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suggests that these and other divalent cations can also
impair P2X7 by allosteric modulation (Acuna-Castillo
et al., 2007; Liu et al., 2008; Moore and Mackenzie,
2008; Yan et al., 2011).
Finally, it should be noted that a number of compounds potentiate ATP-induced P2X7 activation. The
human antimicrobial peptide LL-37 can potentiate
both human and mouse P2X7 activation (Elssner et al.,
2004). In contrast, the murine antimicrobial peptide
CRAMP can enhance human but impair murine P2X7
activation (Seil et al., 2010). The antibiotic polymyxin
B can potentiate human P2X7 activation (Ferrari et al.,
2004), whereas the antiparasitic ivermectin can potentiate human but not murine P2X7 (Norenberg et al.,
2012). A variety of lipids, including lysophostidylcholine
and sphingogosylphopshorylcholine, can also enhance
human and murine P2X7 (Michel and Fonfria, 2007).
The anesthetics ketamine, propofol, and thiopental have
all been shown to increase P2X7-mediated currents
(Nakanishi et al., 2007). Finally, a drug screen of 1040
approved low molecular weight drug compounds recently identified that the antihistamine clemastine can
potentiate human P2X7 activation (Norenberg et al.,
2011). Collectively, the expanding list of compounds that
can either block or potentiate P2X7 activation highlights
the promiscuous nature of this receptor and its ability to
bind a large number of structurally diverse compounds.
X. Use of Modulators of P2X7 Receptor In Vivo
Pharmacological blockade of P2X7 has proved, by
and large, to be efficacious in a range of rodent models
of disease and injury. These studies have been comprehensively summarized in Tables 4–8. In these studies,
a number of P2X7 antagonists with varying specificities
have been used, at a range of concentrations, with
varying injection sites and regimens. However, the
efficacy of these compounds as presented in this
review is potentially skewed, because studies in which
P2X7 antagonists have had no effect may not have
been published. Furthermore, some studies may have
initially investigated the efficacy of multiple antagonists but only reported the outcomes of those that
appeared beneficial. Although the majority of rodent
studies report positive effects, there have been conflicting outcomes between groups for some models of human
disease (e.g., status epilepticus, brain tumors, ischemia,
and spinal cord injury, Tables 4 and 5). In many of the
early studies listed in Tables 4–8, the antagonists used
were relatively nonspecific, being either general P2X or
P2 antagonists (e.g., PPADS, suramin, and oATP).
Thus, the outcomes of these studies cannot definitively
be associated with P2X7 but with P2 receptors in
general. Furthermore, it is likely that some studies that
used nonspecific P2 antagonists have been overlooked
because these reports did not specifically discuss P2X7
(or the former term P2Z).
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Of the first generation antagonists, oATP was the
main compound used for inhibiting P2X7 in vivo, followed
by BBG and PPADS. In the last 6 years, a number of more
specific antagonists have been used in in vivo studies,
supporting the work done in earlier studies. Of these,
A438079 was most commonly used, with generally positive
outcomes reported. However, despite the availability of
these newer antagonists, many recent studies are still
using first generation antagonists, in particular BBG and
oATP. This is likely because of their relatively low cost,
effectiveness in earlier studies, and, in the case of BBG, its
ability to cross the blood-brain barrier (Peng et al., 2009).
Further studies with additional antagonists will be important for supporting a role for P2X7 in disease. This will
be particularly relevant before considering antagonizing
P2X7 in human clinical trials. The following sections
summarize and report the parameters and outcomes of
pharmacological blockade of P2X7 in rodent models of
disease and injury (Tables 4–8). The outcomes of in vivo
studies using P2X7 KO mice in similar models of
disease (which support antagonist studies) are also
discussed.
A. P2X7 Antagonists in Rodent Models of
Neurologic Disease
To the best of our knowledge, the first reported use of
a P2X7 antagonist in a rodent model of neurologic
disease was in 2007 (Matute et al., 2007). Since then,
there have been a number of in vivo studies investigating the effects of pharmacological blockade of P2X7 in
rodent models of neurologic disease (Table 4). These
have largely emerged alongside evidence suggesting
a role for P2X7 in central nervous system disorders (see
Takenouchi et al., 2010). Overall, P2X7 antagonists reduced disease scores and symptoms in rodent models of
multiple sclerosis (experimental autoimmune encephalomyelitis), status epilepticus, brain tumors (glioma),
autism spectrum disorders, mania, depression, and a
range of protein folding diseases (including Alzheimer’s,
Huntington’s, Parkinson’s and prion disease, and amyotrophic lateral sclerosis).
Studies using P2X7 KO mice have supported the
outcomes of P2X7 antagonist studies in models of
neurologic disease. First, in an Alzheimer’s disease model,
injection of amyloid b resulted in an accumulation of IL-1b
in WT, but not P2X7 KO mice (Sanz et al., 2009). This
correlates with the positive outcomes reported in two
different Alzheimer’s disease models that used P2X7
antagonists (Ryu and McLarnon, 2008; Diaz-Hernandez
et al., 2012). Second, in models of depression, P2X7 KO
mice displayed antidepressant-like profiles in comparison with WT controls (Basso et al., 2009; Boucher et al.,
2011; Csölle et al., 2013). Two different P2X7 antagonists (BBG and AZ10606120) also induced an antidepressant phenotype in WT mice (Csölle et al., 2013).
However, the antagonist JNJ-47965567 had no effect
on models of depression, although this antagonist was
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TABLE 4
Antagonism of P2X7 in rodent models of neurologic disease
Disease/Model

Species and
Strain

Sex

Start Age
or Size

Injection
Site

Antagonist &
Dose

C57BL/6
Experimental
mice
autoimmune
encephalomyelitis

N.S.

N.S.

2.5 mg/kg oATP
i.p.
or 10 mg/kg
(oATP)
BBG
or p.o.
(BBG)

C57BL/6
Experimental
mice
autoimmune
encephalomyelitis
Alzheimer’s
Spraguedisease
Dawley
rats

F

8–9
weeks

i.v.

1 mg of oATP

M

280–
300 g

i.p.

50 mg/kg BBG

Alzheimer’s disease

N.S.
J20
transgenic
mice

3–4
i.p.
months

45.5 mg/kg BBG

Huntington’s
disease

N.S.
R6/1
transgenic
mice

8 months i.p.

45.5 mg/kg BBG
or 34.2 mg/kg
A438079

Parkinson’s
disease

SpragueDawley
rats

M

8–12
weeks

i.p.

30 mg/kg
A438079

Prion disease

C57BL/6
mice

N.S.

N.S.

i.p.

100 mg/kg BBG

Amyotrophic
lateral sclerosis

B6SJL-TgN M and 90 days
F
SOD1/
G93A1Gur
mice

i.p.

45.5 mg/kg BBG

Pilocarpine-induced
seizures

C57BL/6J
mice

M

8–13
weeks

i.c.v.

Pilocarpine-induced Spraguestatus epilepticus
Dawley
rats

M

9–11
weeks

i.c.v.

5 mM oATP,
10 mM
A438079 or
10 mM
A740003
5 mM oATP

Pilocarpine-induced Spraguestatus epilepticus
Dawley
rats

M

9–11
weeks

i.c.v.

5 mM oATP, 10
mM A438079
or 10 mM
A740003

Injection
Regimen

oATP every
12 hours or
BBG daily
from 21 to
40 days postMOG/IFA
injection
Once 10 days
post-MOG/
CFA injection
With amyloid-b
followed by daily
injections
for 7 days

Outcomes

Restored axonal
conductance,
reduced
demyelination,
and improved
neurologic score

Reduced
demyelinization
and disease score
Reduced P2X7
immunoreactivity,
microgliosis,
astrogliosis, and
albumin leakage
and improved
neuronal viability
Every 48 hours
Reduced
for 4 months
hippocampal
amyloid plaques
and glycogen
synthase kinase
3 activity
BBG and A438079
BBG every
48 hours and
prevented weight
A438079 every
loss. BBG, but
24 hours for
not A438079,
4 weeks
improved motor
coordination and/
or prevented
neuronal
apoptosis
Partially prevented
1 hour before and
striatal
1 hour after
dopaminergic
6-OHDA
depletion but not
injection
associated with
a reduction of
dopaminergic
cell loss
Prevented cerebral
3/week for
protease-resistant
3 weeks, then
prion protein
2/week for
formation but
4 weeks at 100
did not prevent
dpi (Fukuokadisease
1 strain)
progression
Every 48 hours
Improved motor
function (rotarod
and grip-strength)
in both sexes but
had no effect on
survival, delayed
body weight loss
in males
Increased seizure
Infused over
susceptibility and
1 week before
induced
PILO injection
epileptiform
(rate N.S.)
discharge
0.5 ml/h for 1 week Reduced
neutrophilic and
beginning 3 days
monocytic
before PILO
infiltrates in
injection
frontoparietal
cortex but not in
piriform cortex
0.5 ml/h for 2 weeks Reduced TNF-a in
beginning 3 days
dentate granule
before PILO
cells and
injection
increased
neuronal death

References

Matute
et al., 2007

Lang et al.,
2010
Ryu and
McLarnon,
2008

DiazHernandez
et al., 2012

DíazHernández
et al., 2009

Marcellino
et al., 2010

Iwamaru
et al., 2012

Cervetto
et al.,
2013b

Kim and
Kang, 2011

Kim et al.,
2010

Kim et al.,
2011
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TABLE 4—Continued
Disease/Model

Species and
Strain

Sex

Start Age
or Size

Injection
Site

Antagonist &
Dose

Injection
Regimen

Outcomes

References

Engel et al.,
A438079 (pre- or
2012
post-treatment)
and BBG
(pretreatment),
but not PPADS,
reduced seizure
time, seizureinduced neuronal
death, and
reactive microglia
JimenezA438079 reduced
Pacheco
electrographic
et al., 2013
and clinical
seizure severity,
A438079 and BBG
reduced seizureinduced neuronal
death
Inhibited tumor
Ryu et al.,
growth
2011

Kainic acid-induced C57BL/6
status epilepticus
mice

M

20–25 g

i.c.v.

5 min before or 15
1.75 nmol of
min or 1 hour
A438079, 1
after kainic acid
pmol of BBG, or
injection
1.75 and 3.5
nmol of PPADS

Kainic acid-induced C57BL/6
status epilepticus
mice

N.S.

Adult

i.c.v.

1.75 nmol of
A438079 or 1
pmol of BBG

2 ml 10 min before
and 60 min after
kainic acid
injection

Glioma

SpragueDawley
rats

M

250–300 g i.p.

50 mg/kg BBG

Glioma

SpragueDawley
rats

F

200–300 g i.c.

10 mg of oATP

Autism spectrum
disorders

C57BL/6J
mice

M and 6 weeks
F

i.p.

10 or 20 mg/kg
suramin

Amphetamineinduced
hyperactivity
(mania)
Depression

SpragueDawley
rats

M

Adult

s.c.

30 mg/kg JNJ47965567

Immediately after
implantation of
C6 cells, then 2/
day
Fang et al.,
Coinjected with C6 Reduced activated
2011
cells
microglia,
macrophages, and
MIP-1a or MCP-1expressing cells at
tumor site and
reduced tumor
size 7 dpi
Naviaux
Weekly
Improved social
behavior and
et al., 2013
sensorimotor
coordination
deficits, prevented
cerebellar
Purkinje cell loss,
and restored
normal body
temperature,
synaptosomal
structure, and
various metabolic/
signaling
parameters
1 hour before DReduced hyperactivity Bhattacharya
et al., 2013
but not basal
amphetamine
locomotor activity
sulfate injection

SpragueDawley
rats

M

N.S.

s.c.

C57BL/6
mice

M

2–3
i.p.
months

No effect on
3, 10, or 30 mg/kg 24 hours and 30
immobility,
JNJ-47965567
min before forced
climbing, or
swim test
swimming
behavior
1/day for 4 days or Resulted in an
2 mg/kg
antidepressant
once before
AZ10606120 or
phenotype
testing/treatment
50 mg/kg BBG

Depression

Bhattacharya
et al., 2013

Csölle et al.,
2013

6-OHDA, 6-hydroxydopamine; BBG, Brilliant Blue G; CAMKII, calcium-calmodulin kinase II; CFA, complete Freund’s adjuvant; dpi, days postinfection/injection; EGFR,
epidermal growth factor receptor; ERK1/2, extracellular response kinase 1 and 2; HIF-1a, hypoxia induce factor-1; i.c., intracerebral; IFA, incomplete Freund’s adjuvant; MCP1, monocyte chemoattractant protein-1; MIP-1a, macrophage inflammatory protein-1a; MOG, myelin oligodendrocyte glycoprotein35–55; N.S., not stated; oATP, periodateoxidized ATP; PILO, pilocarpine; PPADS, pyridoxal phosphate-6-azophenyl-2-4-disulfonic acid; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.

efficacious and slightly effective, respectively, in models
of mania and neuropathic pain (Bhattacharya et al.,
2013). To the best of our knowledge, this is the only
documented use of JNJ-47965567, and it is possible that
the injection regimen used was not sufficient to see an
efficacious response in this disease model.
The role for P2X7 in neurologic disease in rodents,
however, is complicated by other varying results with

P2X7 antagonists or P2X7 KO mice. For example, in
a single study of experimental autoimmune encephalomyelitis (Matute et al., 2007), two different P2X7
antagonists were efficacious. In support of this finding,
the incidence of experimental autoimmune encephalomyelitis was reduced 4-fold in GSK P2X7 KO mice
compared with WT mice (Sharp et al., 2008). However,
Pfizer P2X7 KO mice developed more severe experimental

220–250 g i.s.

F

Spinal cord injury

SpragueDawley
rats

280–320 g Brain (nucleus
accumbens)

M

Mechanical
injury-induced
astrogliosis
Mechanical injury- induced
microglial activation

280–320 g Brain (nucleus
accumbens)

Brain (cortex)

Wistar rats

Adult

M
M

280–320 g i.p.

M

SpragueDawley
rats
Wistar rats

280–320 g i.p.

M

Brain trauma

2–3
weeks

N.S.

i.p.

i.c.v.

SpragueDawley
rats

SpragueDawley
rats
SpragueDawley
rats

260–
320 g

M

i.v.

20–28 g

M

Subarachnoid hemorrhage

Subarachnoid hemorrhage

Anoxia-induced
brain injury

Global cerebral
ischemia/
reperfusion

C57BL/6
and
Balb/c
mice
SpragueDawley
rats

Focal cerebral
ischemia

260–300 g i.c.v.
270–300 g i.p.

M

Wistar rats

i.c.v.

Injection Site

270–290 g i.p.

25–30 g

Start Age
or Size

M

M

Wistar rats

Wistar rats

M

Sex

C57/SV129
mice

Species
and Strain

Focal cerebral
ischemia

Focal cerebral
ischemia and
excitotoxic brain
injury
Focal cerebral
ischemia
Focal cerebral
ischemia

Disease/Model

Antagonists did not affect
ischemic or excitotoxic cell
death

Outcomes

2 nM oATP and PPADS

2 ml immediately before or 1 h
after weight-drop

Reduced injury-induced P2X
receptor expression and
inhibited agonist-induced
microglial activation
Improved functional recovery
and reduced cell death

1 ml at 12 ml/h 15 min before or Reduced injury- and agonistwith agonists
induced astrocyte activation

30 pmol of PPADS or 1 pmol 1 ml at a rate of 12 ml/h before
of BBG
P2X agonists

0.03 nmol PPADS

5 min after MCAO

1 ml before and 30 min after
MCAO and 0.5 ml before
methanoglutamate infusion

Injection Regimen

Improved neurologic score and
reduced infarct volume
2 ml 60 min after onset of MCAO Exacerbated behavioral
dysfunction and
ischemic neural injury
Reduced histologic brain
30 mg/kg BBG
Every 12 hours for
damage and neurologic score
3 days beginning
30 min after MCAO
35 mg/kg BBG
Daily for 3 days
Increased endogenous ciliary
after MCAO
neurotrophic factor but no
effect on histologic brain
damage
10 mg of BBG, 1 mg of oATP, 2 ml at 0.5 ml/min 10 min before Reduced neuron death,
or 3 mg of A438079
four-vessel occlusion
neuronal DNA cleavage,
glial activation, hippocampal
cytokine overexpression,
and behavioral deficits and
improved survival rate
Inhibited whole-brain
10 mM oATP
100 ml 1 hour before anoxiaaquaporin 4 downregulation
induced brain ischemia and
reperfusion injury
30 mg/kg BBG
0.5, 24, and 48 hours after
Improved neurobehavioral
subarachnoid hemorrhage
functions, reduced brain
edema, subcortical neuronal
apoptosis, p38 MAPK
activation and cleaved
caspase-3, and increased
Bcl-2
5, 30, or 100 mg/kg BBG
30 min after subarachnoid
30, but not 5 or 100, mg/kg
hemorrhage
improved neurologic score
and brain edema, and
decreased caspase-1, IL-1b,
IL-18 and neutrophil
infiltration
3
2 mm foam soaked in 1 mM After corticectomy into surgery Reduced MCP-1 expression
suramin
site

10 and 100 mg/kg Reactive
Blue 2
100 mM oATP

3 mM oATP, 30 mM or
10 mM PPADS, or
2 mM KN-62

Antagonist and Dose

TABLE 5
Antagonism of P2X7 in rodent models of neurologic injury
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Wang et al.,
2004

Franke et al.,
2007

Franke et al.,
2003

Panenka et al.,
2001

Chen et al.,
2013b

Chen et al.,
2013a

Lee et al.,
2008b

Chu et al., 2012

Kang et al.,
2013

Arbeloa
et al., 2012

Melani
et al., 2006
Yanagisawa
et al., 2008

Le Feuvre
et al., 2003
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SpragueDawley
rats
SpragueDawley
rats

Neuropathic pain

Orofacial pain

Neuropathic pain

SpragueDawley
rats
SpragueDawley
rats

SpragueDawley
rats
SpragueDawley
rats

Neuropathic pain

Neuropathic pain

Wistar rats

Neuropathic pain

Neuropathic pain

Neuropathic pain

Neuropathic pain

Neuropathic pain

Neuropathic pain

C57BL/6
mice
SpragueDawley
rats
Rats

SpragueDawley
rats
SpragueDawley
rats
Rats

Nerve fusion

Sex

i.v.

Injection Site

N.S.

F

180–350 g i.t.

N.S.
200–250 g i.t.

M

N.S.
M

s.c.

180–220 g i.t.

N.S.

i.p. or p.o.

250–350 g i.p.

N.S.

M

N.S.

200–250 g s.c.

M

i.p.l.

8 weeks

250–400 g i.p. or i.v.

M

N.S.

200–300 g i.p. or p.o.

M

i.p.

N.S.

N.S.

Nerve bathed
directly

220–250 g i.v.

220–250 g i.s.

Adult

Start Age
or Size

F

N.S.
SpragueDawley
rats
Fischer rats F

Spinal cord injury

Spinal cord injury

Spinal cord injury

Disease/Model

Species
and Strain

7–14 days after spinal nerve
ligation
2 weeks after nerve ligation/
constriction or vincristine
infusion
2 weeks after nerve ligation/
constriction or vincristine
infusion

10–300 mmol/kg A438079

35 mg of A438079

3, 30, or 100 mg/kg JNJ47965567

Reduced tactile allodynia

Did not alter mechanical
hypersensitivity

Improved hindlimb motor
function recovery and reduced
spinal cord tissue loss
Did not improve locomotion or
secondary histopathological
changes after 7 weeks
Did not improve motor recovery
or histopathological outcome
after 6 weeks
Decreased compound action
potential amplitudes and
improved behavioral recovery
Dose-dependently reversed
mechanical allodynia
Dose-dependently attenuated
mechanical allodynia in all
models
Dose-dependently attenuated
mechanical allodynia in all
models (i.p.) and reduced
activity of spinal neurons
after spinal nerve ligation
(i.v.)
Reduced hyperalgesia

Outcomes

Slightly attenuated mechanical
allodynia at lower doses
Partially attenuated mechanical
allodynia and thermal
hypersensitivity
Prevented spinal long-term
potentiation and reduced
mechanical allodynia; BBG
also inhibited the
upregulation of microglial
P2X7 and expression of Iba-1,
phosphorylated p38, IL-1b
and GluR1
Once after spinal nerve ligation 30, but not 3 or 100, mg×kg21
reduced mechanical allodynia
after 30–60 min
Immediately after CCI of the
Inhibited tactile allodynia/
infraorbital nerve
hyperalgesia and prevented
TNF-a upregulation in
trigeminal sensory nuclear
complex

10–100 (i.p.) or 100 mmol/kg After spinal nerve ligation, once
(p.o.) Compound 53
(i.p.) or twice daily for 4 days
(p.o.) before testing
6.25–50 mg/kg PPADS or
7 days after partial ligation of
1–100 mg/kg BBG
sciatic nerve
10 mM BBG
10 ml daily for 14 days starting
right after chronic constriction
of sciatic nerve
300 mM oATP or 20 mM
5 ml/min for 4 min 0.5 hours
BBG
before tetanic stimulation of
sciatic nerve

30 mg/kg AACBA

4 mg/kg oATP

10–300 mmol/kg A438079

Daily, starting day of sciatic
nerve constriction
22–24 days after spinal nerve
ligation

After sciatic nerve transection
and before nerve rejoining

100 mM Brilliant Blue

4–105 (i.p.) or 142 mg/kg
(p.o.) A740003

15 min after weight-drop and
then at 24 and 72 hours

10–15 min after weight-drop
and once daily for the next 2
days
30 min after weight-drop

Injection Regimen

10 or 50 mg/kg BBG

10 mM PPADS or 0.2 mM
BBG

10 or 50 mg/kg BBG

Antagonist and Dose

TABLE 5—Continued
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Bhattacharya
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Chu et al., 2010

Andó et al.,
2010
He et al., 2012

Perez-Medrano
et al., 2009

Fulgenzi et al.,
2008
Broom et al.,
2008

McGaraughty
et al., 2007

Nelson et al.,
2006
Honore et al.,
2006

Rodriguez-Feo
et al., 2013

Marcillo et al.,
2012

Marcillo et al.,
2012

Peng et al.,
2009
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BzATP-induced IL-1b
release

BzATP; 29(39)-O-(4-benzoylbenzoyl) ATP; CCI, chronic constriction injury; GFAP, glial fibrillary acidic protein; Iba-1, ionized calcium-binding adapter molecule 1; IL, interleukin; i.p.l., intraplantar; i.s., intraspinal; MAPK,
mitogenactivated protein kinase; MCAO, middle cerebral artery occlusion; MCP-1, monocyte chemoattractant protein-1; N.S., not stated; PKC, protein kinase C; TNF, tumor necrosis factor.

Bhattacharya
100, but not 30, mg/kg
et al., 2013
attenuated IL-1b release from
hippocampus
30 min before Bz-ATP
280–320 g s.c.
M

25 mg/kg BBG
180–350 g i.t.
Morphine tolerance

Acute thermal nociception

SpragueDawley
rats
SpragueDawley
rats

M

30 or 100 mg/kg JNJ47965567

Chen et al.,
2012

Andó et al.,
2010

25 and 50 mg/kg PPADS
elevated heat threshold;
10 mg/kg BBG reduced heat
threshold
2/day for 5 days, 30 min before Reduced tolerance to morphine
each morphine dose
analgesia
30 min before hot-plate test

6.25–50 mg/kg PPADS or
3–100 mg/kg BBG
170–300 g i.p.
M

Honore et al.,
2006
Did not affect paw withdrawal
latencies in response to heat
30 min before hot-plate test
200–300 g i.p.
Acute thermal nociception

Disease/Model

SpragueDawley
rats
Wistar rats

M

142 mg/kg A740003

Antagonist and Dose
Sex

Injection Site
Start Age
or Size
Species
and Strain

TABLE 5—Continued

Injection Regimen

Outcomes

References
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autoimmune encephalomyelitis than WT mice (Chen and
Brosnan, 2006). In another example, Pfizer P2X7 KO mice
were more susceptible to seizures than WT littermates in
a model of status epilepticus (Kim and Kang, 2011). This
finding was supported by the use of three P2X7 antagonists
(oATP, A438079, and A740003), each of which enhanced
disease symptoms in status epilepticus (Kim and Kang,
2011; Kim et al., 2011). In contrast, opposite outcomes were
reported using two antagonists (BBG and A438079) in this
disorder (Engel et al., 2012; Jimenez-Pacheco et al., 2013).
B. P2X7 Antagonists in Rodent Models of
Neurologic Injury
In addition to neurologic diseases, there have been
a number of studies investigating the effects of pharmacological blockade of P2X7 in rodent models of
neurologic injuries (Table 5) induced by both focal and
global ischemia/reperfusion, excitotoxicity, subarachnoid
hemorrhage, and mechanical trauma (e.g., corticectomy,
stab wound, and weight drop models). In addition, there
have been a number of pain models investigated, including nerve ligation- and chemical-induced models of
neuropathic pain and acute pain induced by heat. Lastly,
P2X7 blockade in a model of morphine tolerance has
been investigated. P2X7 antagonists were largely efficacious in these models, reducing injury scores, symptoms,
and pain. In these studies, pain is often characterized by
an increased sensitivity to painful stimuli (hyperalgesia)
or a pain reaction in response to normally innocuous
stimuli (allodynia). Notable differences were observed
for models of ischemic and excitotoxic brain injury and
mechanical-induced spinal cord injury. In these studies,
P2X7 antagonists were reported to either exacerbate or
reduce symptoms, despite similar protocols. Furthermore, these conflicting outcomes were observed despite
the use of multiple antagonists in some studies (including
Le Feuvre et al., 2003; Wang et al., 2004; Chu et al.,
2012; Marcillo et al., 2012). Thus, notwithstanding given
differences between laboratories, the cause of these
opposing observations remains unknown.
The efficacy of P2X7 antagonists in models of ischemic
brain injury and neuropathic pain are supported by
similar studies using P2X7 KO mice. In one study,
neurologic deficits, neuronal death, and the overproduction of Fas ligand (CD95L), Fas-associated protein with
death domain and caspase-8 were reduced in P2X7 KO
mice compared with WT littermates after microsphere
embolism (Lu et al., 2012). Likewise, P2X7 antagonists
were efficacious in models of ischemia in three independent studies (Melani et al., 2006; Arbeloa et al.,
2012; Chu et al., 2012). These findings contrast with
another study in which P2X7 KO mice had similar
amounts of cell death induced by temporary cerebral
ischemia compared with WT mice (Le Feuvre et al.,
2003). In this same study, P2X7 antagonists (oATP,
PPADS, and KN-62) similarly had no effect on ischemic
cell death. However an IL-1 receptor antagonist reduced
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TABLE 6
Antagonism of P2X7 in rodent models of compound-induced inflammation
Disease/Model

Species
and Strain

Sex

Start
Age
or Size

Injection
Site

Antagonist and Dose

Injection Regimen

Outcomes

References

Formalininduced
pain

SpragueDawley
rats

M

100–
200 g

s.c.,
50–500 nmol
hindpaw
of suramin or
5–500 nmol of
PPADS

Sawynok and
Reid, 1997

Formalininduced pain

SpragueDawley
rats

M

250–
400 g

i.p.

McGaraughty
et al., 2007

Formalininduced pain

BALB/cJ
mice

N.S. 6–8
weeks

s.c.

C57BL/6
Acetic acidmice
induced
visceral pain
LPS-induced
Wistar
inflammation
rats

N.S. 8 weeks i.p.
M

280–
320 g

i.p.

LPS-induced
Wistar
inflammation
rats

M

200–
300 g

s.c.

LPS-induced
Wistar
inflammation
rats

M

200–
300 g

i.p.

LPS-induced
C57Bl/6J
inflammation
mice

M

2–3
months

i.p.

LPS-induced
C57BL/6
inflammation
mice

N.S.

N.S..

i.p.

SpragueLPS-induced
Dawley
CNS
rats
inflammation

M

240–
260 g

LPS-induced
Wistar
CNS
rats
inflammation

M

N.S.

Wistar
Carrageenanrats
induced
inflammation

M

;250 g

i.c.v.

i.t.

i.p.l., p.o.,
or i.v.

Dose-dependently
Coadministered with
inhibited
formalin or formalin/
amplification of the
ATP
formalin response
(flinching) by ATP
but not to formalin
alone
Dose-dependently
30–300 mmol/kg
After injecting
attenuated
A438079
formalin into hind
nocifensive
paw
behaviors (paw
flinching, licking,
guarding)
300 mmol/kg A438079 30 min before
Attenuated
formalin injection
nocifensive
behaviors (licking,
biting)
Reduced writhing
4 mg/kg oATP
30 min before
responses
inducing visceral
pain
5 min before i.p. LPS Attenuated fever (all),
5, 25, or 100 mg/kg
injection
increased plasma
suramin; 5 or 25
IL-1b and IL-6
mg/kg PPADS; or 40
(PPADS, BBG), and
or 100 mg/kg BBG
increased plasma
TNF-a (BBG)
1–30 mg/kg AACBA
1 hour before i.p. LPS Dose-dependently
injection
reduced plasma
IL-6 release
Reduced hippocampal
25 mg/kg PPADS, 100 30 min (PPADS and
IL-1b release; BBG
BBG) or 2 hours
mg/kg BBG, or 0.9
also reduced basal
(oATP) before i.p.
mg/kg oATP
release
LPS injection
Reduced hippocampal
100 mg/kg BBG, 0.9
30 min (BBG) or 2
IL-1b release; also
mg/kg oATP
hours (oATP) before
reduced basal
i.p. LPS injection
release
100 mmol/kg A438079 1 hour before i.p. LPS Impaired body
injection
temperature
increase
1 mM oATP
30 min before striatal Reduced activated
LPS injection
microglia,
phosphorylation of
p38 MAPK, iNOS
production,
nitration of
proteins, lipid
peroxidation,
oxidative DNA
damage, and
caspase-3 activation
and increased
neuronal survival
50 mg of oATP or 50 mg With or without LPS Attenuated
of A438079
24 h after 1st i.t.
mechanical
LPS injection
hyperalgesia and
prevented
phosphorylation of
p38 MAPK in
microglia
Reduced thermal
50–200 mM oATP
3 hours after i.p.l.
hyperalgesia (all
carrageenan
routes), expression
injection
of chemokines and
P2X7, and
macrophage
infiltrates (i.p.l, i.v.)

Hansen et al.,
2011
Fulgenzi
et al., 2008
Gourine et al.,
2005

Broom et al.,
2008
Csölle and
Sperlágh,
2010
Csölle and
Sperlágh,
2010
BarberàCremades
̀
et al., 2012
Choi et al.,
2007

Clark et al.,
2010

Fulgenzi
et al., 2005

(continued )
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TABLE 6—Continued

Disease/Model

Species
and Strain

Sex

Start
Age
or Size

Injection
Site

Antagonist and Dose

Injection Regimen

SpragueCarrageenanDawley
induced
rats
inflammation

M

200–
300 g

i.p.

14–142 mg/kg
A740003

90 min after i.p.l.
carrageenan
injection

SpragueCarrageenanDawley
induced
rats
inflammation

M

200–
250 g

s.c.

3–100 mg/kg AACBA

30 min before
(prophylactic) or
1–1.5 hours after
(therapeutic) i.p.l.
carrageenan
injection

Albino
CarrageenanWistar
induced
rats
inflammation
Wistar
Carrageenanrats
induced
inflammation

M

200–
250 g

TMJ

100, 300, and 900 mg
of A438079

Coinjected with
carrageenan

M

200–
250 g

Coinjected with
s.c.,
0.5, 2, or 6 mg/paw
carrageenan
hindpaw
oATP or 100 or 300
mg/paw A438079

M

275–
420 g

i.t.

M

6–8
weeks

i.p.

M

250–
300 g

i.t.

MO-induced
Spragueinflammation
Dawley
rats
Swiss
CO-induced
mice
irritant
contact
dermatitis

Venom-induced SpragueDawley
pain and
rats
inflammation

1 mM BBG or 100 mM Continuous
oATP
superfusion over
MDH for 2 hours
80 mmol/kg A438079
2 hours after CO
application

0.1, 1, or 10 mg of
A438079

10 min before venom
injection

Outcomes

References

Honore et al.,
Dose-dependently
2006
reduced thermal
hyperalgesia and
paw edema
Broom et al.,
Prophylactically and
2008
therapeutically
reduced mechanical
hypersensitivity,
and therapeutically
reduced paw
swelling
Did not alter TMJ
Teixeira et al.,
hyperalgesia
2010a
Reduced hyperalgesia
and the concentration
of TNF-a, IL-6, and
CINC, but not IL-1b,
in hindpaw
Attenuated MDH
central
sensitization
Reduced neutrophil
infiltration,
myeloperoxidase
levels, IL-1b, Gr1+
cell recruitment,
dendritic cells, and
macrophages and
decreased ear
edema
Dose-dependently
inhibited
spontaneous
flinching and
mechanical
allodynia but not
edema

Teixeira et al.,
2010b

Itoh et al.,
2011
Da Silva et al.,
2013

Zhou et al.,
2012

CINC, cytokine-induced neutrophil chemoattractant 1; CNS, central nervous system; CO, croton oil; IL, interleukin; iNOS, inducible nitric-oxide synthase; i.p.l.,
intraplantar; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase; MDH, medullary dorsal horn; MO, mustard oil; N.S., not stated; TMJ, temporomandibular
joint; TNF, tumor necrosis factor.

cell death, suggesting IL-1a and IL-1b can be secreted
via a P2X7-independent mechanism during cerebral
ischemia in mice. In models of neuropathic pain, P2X7
KO mice lacked hypersensitivity to thermal and mechanical stimuli compared with WT mice (Chessell et al.,
2005; Fulgenzi et al., 2008; Hansen et al., 2011). These
studies support those that used P2X7 antagonists, in
which a range of antagonists attenuated neuropathic
pain (Table 5).
C. P2X7 Antagonists in Rodent Models of
Compound-Induced Inflammation
Most laboratories studying the effects of P2X7 antagonists on inflammation in vivo have done so by relatively
simple rodent models involving the injection of compounds such as formalin, acetic acid, lipopolysaccharide
(LPS), carrageenan, mustard oil, croton oil, or venom
(Table 6). In these models, inflammation has largely been
assessed at either a cellular level or by using measures of
pain, fever, or edema, three of the classic hallmarks of
inflammation. In the majority of studies, administration
of P2X7 antagonists reduced inflammatory processes. Of

particular note was the separate use of multiple
antagonists in some studies. These studies reported
an antagonist-dependent reduction in LPS- (Gourine
et al., 2005; Clark et al., 2010; Csölle and Sperlágh,
2010), carrageenan- (Teixeira et al., 2010b), and mustard
oil-induced inflammation (Itoh et al., 2011) and further
support the benefits of targeting P2X7 in inflammation.
In addition to the use of multiple antagonists, the
use of P2X7 KO mice, which demonstrate attenuated
compound-induced inflammatory responses compared
with WT counterparts, also supports the benefits of
targeting P2X7 in inflammation. The majority of P2X7
KO studies investigating the role of P2X7 on inflammation
in vivo have done so by injecting LPS. In these studies,
LPS induced mechanical hypersensitivity, fever, hyporeactivity in response to phenylephrine, increased p38 and
nuclear factor-kB phosphorylation, increased cytokines
[IL-1b, IL-10, and tumor necrosis factor-a (TNF-a)], and
decreased mean arterial pressure and pressor responses
to noradrenaline in WT mice, all of which were attenuated
or absent in P2X7 KO mice (Mingam et al., 2008; Clark
et al., 2010; Barberà-Cremades et al., 2012; Chiao et al.,

P2X7 Antagonists in Models of Disease

2013; Kim et al., 2013). These findings contrast with the
results of one study, which found that LPS induced
similar levels of IL-1b and TNF-a in the serum of WT and
P2X7 KO mice (He et al., 2013). In this study, these
cytokines were attenuated in NLRP3 KO mice, suggesting
that these cytokines can be secreted via a P2X7-independent
mechanism during LPS-induced inflammation in mice
or that compensatory mechanisms operate in P2X7 KO
mice. The role of P2X7 in visceral pain has also been
investigated in P2X7 KO mice. In one study, acetic acidinduced visceral pain, as measured by writhing behavior, was largely absent in P2X7 KO mice compared with
WT littermates (Fulgenzi et al., 2008). This same study
also observed greatly reduced acetic acid-induced visceral
pain in WT mice after pretreatment with the P2X7
antagonist oATP.
D. P2X7 Antagonists in Rodent Models of
Musculoskeletal Disorders
The efficacy of P2X7 antagonists has also been
examined in rodent models of musculoskeletal disorders
such as arthritis, bone cancer, and Duchenne muscular
dystrophy (Table 7). The majority of these studies examined inflammatory arthritis, for which there are two
main types of rodent models employed. In the first model,
intraplantar injection of Complete Freund’s adjuvant
(CFA) is used to induce inflammatory pain and swelling
of the paws. This model is also used to investigate
compound-induced inflammation, but is included here
because of its relevance to musculoskeletal disorders.
In the second model, collagen-induced or anti-collagen
antibody-induced arthritis results in an autoimmune
response against collagen and subsequent joint damage.
These are generally used as models of rheumatoid
arthritis, resulting in pathology similar to that of the
human disease (Williams, 2012). A range of P2X7 antagonists has resulted in improved experimental outcomes in
models of inflammatory arthritis (Table 7). In addition, GSK
P2X7 KO mice do not develop CFA-induced inflammatory
hypersensitivity (Chessell et al., 2005), whereas Pfizer P2X7
KO mice have reduced incidence and severity of anticollagen antibody-induced arthritis compared with WT littermates (Labasi et al., 2002; Fulgenzi et al., 2008). As a result
of these and other studies, the first approved drugs that
target P2X7 have undergone clinical trials in rheumatoid
arthritis patients (see section XI).
E. P2X7 Antagonists in Rodent Models of Disorders
Associated with Other Tissues
Although the majority of in vivo P2X7 antagonist
studies have focused on neurologic and musculoskeletal inflammation and inflammatory disorders, there
are a number of studies that have looked at the effects
of pharmacological blockade of P2X7 in disorders associated with other tissues (Table 8). P2X7 antagonists
reduced symptoms in rodent models of disorders affecting
the bladder (hemorrhagic cystitis), colon (carcinoma), eyes
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(retinitis pigmentosa, photoreceptor degeneration, retinal
ganglion cell death, retinal pigmented epithelium degeneration, subretinal hemorrhage, and optic nerve injury), heart (transplantation, cardiac transplant rejection,
and myocardial ischemia), kidney (glomerulonephritis,
lupus nephritis, hypertension, and renal injury), liver
(obesity and hepatotoxicity), lung (chemical and allergic
inflammation or chronic obstructive pulmonary disease),
pancreas (autoimmune diabetes, islet allograft rejection,
and pancreatitis), and skin (dermatitis, graft-versus-host
disease, and melanoma). Altogether these studies used
a range of antagonists, demonstrating the widespread
effects of P2X7 in a number of tissues and expanding the
number of disorders that may benefit from P2X7 blockade.
Furthermore, a number of these studies also had supporting P2X7 KO mouse data alongside P2X7 antagonist data,
further implicating P2X7 in a number of disease processes.
These include models of hemorrhagic cystitis (Martins
et al., 2012), glomerulonephritis (Taylor et al., 2009b),
hypertension and renal injury (Ji et al., 2012), lung
inflammation (Lucattelli et al., 2011), allergic airway
inflammation (Müller et al., 2011), pancreatitis (Hoque
et al., 2011), and graft-versus-host disease (Wilhelm et al.,
2010).
XI. P2X7 Antagonists in Human Clinical Trials
Because of the potential benefits of P2X7 blockade
in rodent studies, the use of drugs targeting P2X7 in
humans has commenced for a number of disorders,
including arthritis, pain, and multiple sclerosis (Baas,
2012). Of these trials, only two have been published as
full-length reports, with both reporting the clinical
efficacy and safety of the P2X7 antagonists AZD9056 or
CE-224,535 in rheumatoid arthritis patients (Keystone
et al., 2012; Stock et al., 2012). However, both of the
trials failed to find any therapeutic benefit with these
compounds (Keystone et al., 2012; Stock et al., 2012).
The first of these trials were two phase II studies in
patients with rheumatoid arthritis treated with the
AstraZeneca compound, AZD9056 (Keystone et al.,
2012). Despite a significant reduction in swollen and
tender joint count in the phase IIa study, there was
no significant benefit on disease in the phase IIb study.
With the exception of one patient, who required hospitalization for nausea and vomiting after treatment
with AZD9056, there were no significant side effects.
The second clinical trial reported was a phase IIa
study in patients with rheumatoid arthritis treated
with the Pfizer compound, CE-224,535 (Stock et al.,
2012). There was no significant benefit on disease
with this compound. Furthermore, treatment with
CE-224,535 resulted in a small but acceptable increase in the rate of nausea and diarrhea. In both
clinical trials there were no serious infections or deaths
related to adverse events (Keystone et al., 2012; Stock
et al., 2012).

9 weeks

M

Every 48 hours for 3 weeks

Every 3 days from 3–14 weeks of age

IL, interleukin; i.p.l., intraplantar; i.t., intrathecal; MO, mustard oil; N.S., not stated; p.o., per os; TNFR, tumor necrosis factor receptor.

i.p.

45.5 mg/kg BBG

125 mg/kg Coomassie
Brilliant Blue

i.p.

3 weeks

M

mdx
transgenic
mice
mdx
transgenic
mice

Duchenne
muscular
dystrophy
Duchenne
muscular
dystrophy

14 days post bone cancer operation

300 mmol/kg A438079

3 mM oATP

N.S. 6–8 weeks s.c.

i.p.

BALB/cJ and
C3H/HeN
mice

8 weeks

Bone cancer
pain

M

Before collagen injection and
once a day after for 21 days
(prophylactic) or once a day
from 13–21 days after
injection (therapeutic)
100 ml daily for 10 days
starting at onset of visible
clinical signs

30 mg/kg AACBA

DBA/1J mice

125–175 g

s.c.

F

10 days after inducing
arthritis

Lewis rats

4 mg/kg oATP

i.p.l., p.o.,
or i.p.

M

8 weeks

20 weeks after knee joint
cavity CFA injection

50 mg of A438079

i.t.

N.S. 6–8
weeks
(20–25 g)

B6129SF2/J
WT and
TNFR1/R2
KO mice
C57BL/6 mice

48 hours after i.p.l.
CFA injection

10–100 mmol/kg
A839977
48 hours after i.p.l.
CFA injection

M

s.c.

48 hours after i.p.l.
CFA injection

30–300 mmol/kg
A839977

Collagen-induced
arthritis

Anticollagen
antibodyinduced
arthritis
Collagen-induced
arthritis

20–25 g

M

i.p

47.5 hours after i.p.l.
CFA injection

14–142 mg/kg
A740003

24 hours after i.p.l.
CFA or 3 hours after
i.v. CFA/fucoidin
injection

24 hours after i.p.l.
CFA injection

Injection Regimen

3–100 mg/kg BBG

CFA/MO-induced
chronic arthritis

CFA-induced
inflammation

CFA-induced
inflammation

200–300 g

M

i.p.

200–300 g

M

168 mM oATP

56–336 mM oATP

Antagonist and Dose

i.p.

SpragueDawley
rats
SpragueDawley
rats
BALB/c and
IL-1ab KO
mice
Wistar rats

CFA-induced
inflammation

i.p.l. or i.v.

;250 g

M

M

Injection
Site

i.p.l.

Start Age
or Size

;250 g

Sex

200–250 g

Wistar rats

CFA-induced
inflammation

CFA-induced
inflammation

Wistar rats

Species and
Strain

CFA-induced
inflammation

Disease/Model

TABLE 7
Antagonism of P2X7 in rodent models of musculoskeletal disorders

Reduced clinical score, cartilage
erosion, infiltrating T cells,
and serum type II collagen
IgG autoantibodies
Did not improve limb use score
or weight-bearing ratio after
acute treatment in models
with (BALB/cJ) and without
(C3H/HeN) astrocyte
activation
Reduced number of
degeneration-regeneration
cycles in skeletal muscles
Blocked CD62L shedding from
blood T cells and restored
their capability to migrate
to the heart

Dose-dependently reduced
thermal hyperalgesia in
WT but not IL-1ab KO mice
Dose-dependently reduced
hyperalgesia but had no
effect on edema
Reduced thermal hyperalgesia
and mechanical allodynia for
.3 hours in TNFR1/R2 KO
mice
Increased paw withdrawal
latency (i.e., reduced
hyperalgesia) (all routes) up
to 24 hours post-treatment
Prophylactically, but not
therapeutically, reduced
clinical and histologic
scores

Dose-dependently increased
paw pressure threshold
(reduced hyperalgesia) in
inflamed paws
Increased paw pressure
threshold (reduced
hyperalgesia) and reduced
edema and ATP levels in
inflamed paws
Dose-dependently reduced
thermal hyperalgesia but
not paw edema
Dose-dependently reduced
thermal hyperalgesia

Outcomes

Cascabulho et al., 2012

Young et al., 2012

Hansen et al., 2011

Ardissone et al., 2011

Broom et al., 2008

Fulgenzi et al., 2008

Westlund et al., 2012

Andó et al., 2010

Honore et al., 2009

Honore et al., 2009

Honore et al., 2006

Dell’Antonio et al.,
2002a

Dell’Antonio et al.,
2002b

References
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N.S.
M

M

C57BL/6J mice

C57BL6JJcl mice

Wistar rats

Optic nerve injury

F

M

Wistar rats

Piebald Virol Glaxo
rats

N.S.

Long Evans rats

BzATP-induced
retinal ganglion
cell death
Pressure-induced
retinal ganglion
cell death

Retinal pigmented
epithelium
degeneration
Subretinal
hemorrhage
(age-related
macular
degeneration)
Optic nerve crush
injury

N.S.

Sprague-Dawley rats

ATP-induced
photoreceptor
degeneration

F

M

Sex

N.S.

BALB/c mice

Swiss and
C57/BL6 mice

Species and Strain

rd1 transgenic mice

Eyes
Retinitis pigmentosa

Colon
Colon
carcinoma

Bladder
Cyclophosphamideinduced
hemorrhagic
cystitis

Disease/Model

160–200 g

280–320 g

8 weeks

s.c.

Vitreous
body

Subretinal
space

i.vi.

i.vi.

10–12 weeks

N.S.

i.vi.

i.vi.

i.vi.

Tumor

i.p.

Injection Site

14–26 days

8–12 weeks

14–21 days

5–7 weeks,
15–18 g

25–30 g

Start Age or Size

Protected photoreceptors
against apoptosis
Inhibited ganglion cell
death

10 min before ATP
injection
1 ml of coinjected with
BzATP over 20 s

Immediately after injury

10–300 mM oATP
or 0.003–30 mM
BBG

1 mM oATP

0.5 ml/h for 2 weeks after
partial transection of
optic nerve

24 hours before and 72
hours after inducing
RPE degeneration
With autologous blood

Puthussery
and
Fletcher,
2009
Puthussery
and
Fletcher,
2009
Hu et al., 2010

Adinolfi et al.,
2012

Martins
et al., 2012

References

oATP (30 mM) and BBG
(0.003–3 mM) protected
retinal ganglion cells
from death and
suppressed P2X7 upregulation
In combination with
lomerizine and INQ
improved injury
parameters and visual
function

(continued )

Savigni et al.,
2013

Kakurai et al.,
2013

Dose-dependently reduced Sugiyama et
al., 2013
cell loss and P2X7,
TNF-a, IL-1b, and IL-6
mRNA
Kerur et al.,
Protected against Alu
2013
RNA-induced RPE
degeneration
Notomi et al.,
Reduced TUNEL2013
detectable
photoreceptor cell
apoptosis

Increased photoreceptor
survival by 30%

Reduced tumor growth,
angiogenesis, and
VEGF staining

At day 14

200 ml 5, 9, and 13 days
after P2X7overexpressing CT26
cell injection

1 ml of A740003
50 mM BBG

Outcomes

30 min before and 4 hours Reduced
nociceptive behavior
after cyclophosphamide
scores, c-Fos
injection
staining in the spinal
cord and brain, edema
and hemorrhage
indices, tissue IL-1b,
and TNF-a levels
and macrophage
migration

Injection Regimen

1–100 mM oATP or 5 ml after elevating
intraocular pressure
0.3–300 nM
BBG

10 mM BBG or 10
mM MRS 2540

20 mM PPADS
(;1 mM in
retina)

20 mM PPADS
(;2 mM in
retina)

600 mM oATP

50, 100, and
200 mmol/kg
A438079

Antagonist and Dose

TABLE 8
Antagonism of P2X7 in rodent models of disorders associated with other tissues
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Sprague-Dawley rats

Myocardial ischemia

MRL/lpr mice

NZM2328 mice

Lupus nephritis

Lupus nephritis

Kidney
Antibody-mediated
Wistar Kyoto rats
glomerulonephritis

Sprague-Dawley rats

Myocardial ischemia

F

F

M

M

N.S.

N.S.

Sprague-Dawley rats

Start Age or Size

3 months

12 weeks

180–220 g

180–220 g

180–230 g

180–230 g

N.S.

N.S.

C57BL/6 mice

Chronic heart
cardiac
transplant
rejection
Myocardial ischemia

Sex

N.S.

Species and Strain

C57BL/6 and BALB/c N.S.
mice

Heart
Heart
transplantation

Disease/Model

i.p.

i.p.

N.S.

i.p.

i.g.

i.p.

i.p.

i.p.

Injection Site

45.5 mg/kg BBG

45.5 mg/kg BBG

100 and 300
mmol/kg
A438079

30 mg/kg BBG

1 mg/kg oATP

Induced long-term
transplant survival
(80%) and anergy
toward graft antigens,
and reduced Th1/Th17
cells
Prevented coronary
vasculopathy, reduced
cellular infiltrates and
Th1/Th17 cells
Reduced elevation of
systolic blood pressure,
heart rate, cardiac
enzymes, serum TNF-a
and IL-6, and P2X7
Reduced elevation of
systolic blood pressure,
heart rate, TNF-a, IL-6,
serum cardiac enzymes,
P2X7, and improved Q
wave
Reduced elevation of P2X7
and p-ERK1/2 in
superior cervical
ganglia neurons

Outcomes

Kong et al.,
2013

Liu et al., 2013

Tu et al., 2013

Vergani et al.,
2013b

Vergani et al.,
2013b

References

(continued )

Taylor et al.,
On day nephrotoxic serum Prevented
2009b
glomerulonephritis,
injected then 2/day for
with reduced fibrinoid
7 days
necrosis, proteinuria
and glomeruli
macrophage infiltration
(300 but not 100
mmol/kg)
Zhao et al.,
Every 48 hours for 8
Reduced renal damage,
2013
weeks
NLRP3, ASC, caspase
1-p20, IL-1b, immune
complex deposition,
anti-dsDNA antibodies,
Th17:Treg cell ratio and
mortality
Every 48 hours for 3–5
Zhao et al.,
Delayed proteinuria and
2013
reduced urinary
weeks after adenovirusalbumin/creatinine
expressing interferon-a
ratio, serum BUN, antiinjection
dsDNA antibodies,
serum, and renal IL-1b,
and C3 and IgG
deposits

1/day for 7 days after
occluding left coronary
artery

1/day for 20 days

1/day for 20 days 24
hours after occluding
left coronary artery

1/day for 14 days

250 mg of oATP

30 mg/kg BBG

1/day for 14 days

Injection Regimen

250 mg of oATP

Antagonist and Dose

TABLE 8—Continued
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Fischer and Lewis
rats

Renal Injury

M

M

C57BL/6 mice

C57BL/6

Acetaminopheninduced
hepatotoxicity

Acetaminopheninduced
hepatotoxicity

M

M

8–12 weeks

N.S.

LPS-induced airway
inflammation

Human CD39
overexpressing
C57BL/6J mice

N.S.

M

Cigarette smoke- and C57BL/6 mice
LPS-induced
airway
inflammation

6–8 weeks

M

C57/Bl6 mice

Cigarette smokeinduced lung
inflammation

M

300–350 g

8 weeks

5–8 weeks

10 weeks (high-fat
diet), 16 weeks for
antagonist

N.S.

4–10 weeks (high-salt
diet), antagonist
start N.S.

Start Age or Size

Hartley guinea pigs

Lung
Chemical irritantinduced cough

Sex

N.S.

DIO C57BL6/J mice

Liver
Diet-induced obesity

Dahl salt-sensitive
rats

Species and Strain

Salt-sensitive
hypertension and
renal injury

Disease/Model

i.t.

p.o.

i.t.

Aerosol

i.p.

i.p.

i.p.

100 mM A438079

30–1000 mg/kg
A438079

10 mM KN-62

50 mM PPADS

Exposed for 2 min, 5 min No effect on ATP-induced
enhancement of
before ATP and
coughing
irritants
Reduced macrophage and
Before cigarette smoke
neutrophil infiltrates
exposure, 5 times over 3
and cytokines in
consecutive days
bronchoalveolar lavage
fluid
1 hour before first
Dose-dependently
exposure and 1 hour
inhibited airway
after second exposure
neutrophilia induced by
each day for 3 days
cigarette smoke but not
LPS
50 ml with LPS
Reduced neutrophil and
lymphocyte, but not
macrophage,
recruitment; reduced
keratinocyte
chemoattractant levels
2 hours after LPS

1 hour before CCl4
injection

References

(continued )

Théâtre et al.,
2012

Eltom et al.,
2011

Lucattelli et
al., 2011

Kamei et al.,
2005

Xie et al., 2013

Hoque et al.,
2012

Chatterjee et
al., 2012

Ji et al., 2012
Improved creatinine
clearance and
attenuated saltsensitive hypertension,
interstitial fibrosis
(BBG), macrophage and
T-cell infiltration, and
urinary protein
excretion (BBG,
A438079)
Menzies et al.,
Reduced mean arterial
2013
blood pressure, renal
vascular resistance, and
pressure-diuresis
threshold in Fischer but
not Lewis rats

Outcomes

Inhibited formation of
protein radicals and
tyrosine nitration, and
decreased TNF-a and
MCP-2 release from
Kupffer cells
300 mM/kg (2 mg) 1 hour before or 2 hour
Pre- and post-treatment
A438079
after i.p. APAP injection
prevented acute liver
injury and
inflammation
80 mg/kg A438079 1 hour before i.p. APAP
Attenuated liver injury
(plasma ALT activity
and necrosis), GSH
depletion, protein
adducts, JNK
activation, and P450
activities

300 mmol/kg
A438079

Acute infusion

50 mg/min/100 g
BBG

i.v.

Every day for 4 weeks
(BBG) or 7 days
(A438079)

50 mg/kg BBG or
100 mg/kg
A438079

i.p.

Injection Regimen

Antagonist and Dose

Injection Site
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F

C57BL/6 mice

C57BL/6 mice

Melanoma

Melanoma

6 weeks

5–7 weeks, 15–18 g

6–12 weeks

N.S.

5–8 weeks

N.S.

N.S.

i.p.

Tumor

i.p.

Pinna of ear

s.c.

i.p.

i.v.

i.pu. (acute)
or i.t.
(chronic)

Injection Site

Reduced airway
eosinophilia, goblet cell
hyperplasia, bronchial
hyperresponsiveness to
methacholine, and
airway remodeling

Outcomes

Müller et al.,
2011

References

4 hours before TNCB
sensitization

Hattori et al.,
2012

Adinolfi et al.,
2012

Wilhelm et al.,
2010

Weber et al.,
2010

Lang et al.,
Suppressed diabetes in
2010
75% of treated mice by
affecting T-cell
proliferation
Vergani et al.,
1/day for 14 days
Prolonged allograft
2013a
survival and reduced
severity of autoimmune
response (IFN-g, IL-6,
cellular infiltrates, and
Th1 cells)
Hoque et al.,
1 hour before 1st cerulean Reduced pancreatic
2011
injection
edema and leukocyte
infiltrate
4 days after LCMV-WE
infection

Before OVA exposure on
days 19–21 after
sensitization (acute) or
3 days per week for
2 weeks (chronic)

Injection Regimen

Prevented sensitization
and contact
hypersensitivity
Reduced mortality,
10 mmol of PPADS Days 0–10
disease severity (both),
or 1 mmol of
donor T-cell expansion,
KN-62
and IFN-g production
(PPADS)
300 nM
100 ml 5, 7, 9, and 13 days Reduced tumor growth,
AZ10606120
after B16 cell injection
VEGF staining, and
vessel formation
0.5 mg of oATP
5, 15, and 25 days after
Reduced tumor growth
B16 cell injection

3.6 mg of KN-62

300 mmol/kg
A438079

250 mg of oATP

1 mg of oATP

1 mM KN-62

Antagonist and Dose

TABLE 8—Continued

ALT, alanine aminotransferase; APAP, acetaminophen; BUN, blood urea nitrogen; DIO, diet-induced obesity; ERK, extracellular signal-regulated kinase; GSH, glutathione; i.g., intragastric; IL, interleukin; INQ, 2-[7-(1Himidazol-1-yl)-6-nitro-2,3-dioxo-1,2,3,4-tetrahydro quinoxalin-1-yl]acetic acid; i.pu., intrapulmonary; i.vi., intravitreal; JNK, c-jun-N-terminal kinase; LCMV-WE, lymphocytic choriomeningitis virus, strain WE; MCP-2, monocyte
chemoattractant protein 2; OVA, ovalbumin; RPE, retinal pigmented epithelium; STAT3, signal transducer and activator of transcription 3; Th1, T helper type 1; TNCB, 2,4,6-trinitrochloro-1-benzene; TNF, tumor necrosis factor;
TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling.

M

N.S.

BALB/c mice

N.S.

Graft-versus-host
disease

C57BL/6 mice

M

C57BL/6 mice

Acute pancreatitis

N.S.

C57BL/6 and BALB/c N.S.
mice

Skin
Allergic contact
dermatitis

Start Age or Size

F (chronic) 6–8 weeks
N.S.
(acute)

Sex

Islet allograft
rejection

RIP-GP transgenic
mice

BALB/c and C57/Bl6
mice

OVA/alum-induced
allergic airway
inflammation

Pancreas
Autoimmune
diabetes

Species and Strain

Disease/Model
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As a result of these studies, both groups concluded that
P2X7 does not appear to be a useful target in rheumatoid
arthritis (Keystone et al., 2012; Stock et al., 2012).
However, the possibility remains that the efficacy of
these P2X7 antagonists is dependent on P2RX7 genotype, as indicated in other in vitro studies using
GSK1370319A (McHugh et al., 2012). Thus, it may be
essential to stratify clinical data by P2RX7 genotype
to detect therapeutic benefits of P2X7 blockade. The
possibility also remains that P2X7 blockade is of no
therapeutic benefit in patients who are refractory to
methotrexate or sulfasalazine, because both studies used
a patient cohort already nonresponsive to these therapies. Thus, it may be of value to explore if the therapeutic
benefit of P2X7 blockade is influenced by methotrexate or
sulfasalazine resistance. In the meantime, the trial of
AZD9056 or CE-224,535 in other human disorders and
the trial of other compounds, such as those from
GSK (Abberley et al., 2010) and Johnson & Johnson
(Bhattacharya et al., 2013), await.
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modulating P2X7 expression. Recently, the dialdehydic
compound 2-[1-(6-amminopurin-9-il)-2-osso-etossi]prop2-enale (MED1011) was developed and shown to downregulate the expression and function of P2X7 in
macrophages by causing the internalization of P2X7
in these cells (Muzzachi et al., 2013). Moreover, the
medicinal extract from Aloe vera has been shown to
downregulate P2X7 expression in macrophages to attenuate IL-1b secretion (Budai et al., 2013). Alternatively,
P2X7 expression could potentially be down modulated by
use of RNA interference. Small interfering RNA has been
used to specifically downregulate P2X7 in mice and rats
to attenuate diseases such as brain injury (Chen et al.,
2013a) and nephritis (Zhao et al., 2013). Finally, P2X7
expression and its subsequent function could be downregulated by targeting the specificity protein 1 transcription factor (Sp1), which plays an important role in the
transcriptional regulation of P2X7 (Garcia-Huerta et al.,
2012). Of note, targeting Sp1 by small hairpin RNA or the
antibiotic mithramycin, which blocks Sp1 activity, downregulates P2X7 in vitro (Garcia-Huerta et al., 2012).

XII. Modulators of P2X7 Receptor Expression
P2X7 is widely distributed throughout the mammalian body (see section I); however, the relative expression and distribution of this receptor between cell types
and tissues have not been fully elucidated. As also noted
above (section I), future studies of P2X7 reporter mice
expressing enhanced green fluorescent protein (Engel
et al., 2012; Garcia-Huerta et al., 2012; Jimenez-Pacheco
et al., 2013) will be useful for visualizing P2X7 expression
patterns in both healthy and diseased animals. However,
studies comparing the relative expression of P2X7 on
cell types between mice and humans are lacking, and the
possibility remains that this expression may not be
comparable. In humans, P2X7 is present in decreasing
amounts on monocytes, B cells and T cells (Gu et al.,
2000), whereas in dogs P2X7 is present in greatest
amounts on T cells and is present at lower amounts on
monocytes and B cells (Stevenson et al., 2009). Nevertheless, modulation of P2X7 expression may provide an
alternate therapeutic strategy in addition to pharmacological blockade.
A range of inflammatory mediators can modulate P2X7
expression and its subsequent function on various cell
types. Proinflammatory mediators such as interferon-g
(IFN-g), TNF-a, and LPS can upregulate P2X7 on macrophages (Humphreys and Dubyak, 1998), umbilical vein
endothelial cells (Wilson et al., 2007), and epithelial cells
(Welter-Stahl et al., 2009). Conversely, anti-inflammatory
mediators including transforming growth factor-b1, IL-4,
and IL-10 can downregulate P2X7 on macrophages
(Lemaire and Leduc, 2003; Gadeock et al., 2010). As a
result of these and other studies, the possibility remains
that such mediators may be used to regulate P2X7 expression and its subsequent function in a range of
disorders. Other compounds may also be of value in

XIII. Conclusions and Future Directions
Rodent models are valuable tools for investigating
the role of P2X7 in health and disease. However, there
are a number of factors that need to be considered
when interpreting the results of such studies in the
context of human disease. First, unlike human P2X7,
rodent P2X7 can be activated by the alternate ligand
NAD to induce similar downstream signaling events to
that of ATP activation. Second, P2X7 variants, such as
the murine P451L SNP and spice isoforms P2X7K,
P2X7 13B, and P2X7 13C, contribute to the diversity
of receptor-mediated responses, thus adding further
complexity to P2X7 studies in rodents. This is particularly highlighted by the currently available P2X7 KO
mice, in which some of these variants have escaped
deletion. Identification of P2X7 in the guinea pig, dog,
and Rhesus macaque, in addition to the rat and mouse,
highlights the potential of these species for the future
study of P2X7-related diseases and in the mandatory
testing and evaluation of preclinical drugs targeting
P2X7.
In general, a variety of P2X7 antagonists have been
reported to be efficacious in rodent models of neurologic
disease and injury, compound-induced inflammation,
musculoskeletal disorders, and disorders associated
with other tissues. In these studies, there was no clear
consensus on the use of P2X7 antagonists in terms
of doses or injection sites, with a variety of regimens
successfully employed. Although nonspecific P2X7 antagonists were used in a number of these studies, the
outcomes of some have been confirmed in more recent
years through the use of more specific P2X7 antagonists.
This suggests that P2X7 may play a role in a wide variety
of diseases, implicating this receptor as a potential
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therapeutic target in a broad range of settings. However,
differential activity of P2X7 antagonists is observed at
receptors between individuals and species, presumably
as a result of P2X7 variants and variations in amino acid
homology in antagonist binding sites. Thus, this may be
a limitation of translating preclinical studies of P2X7
antagonists in rodents to clinical trials in humans.
Although rodent models and P2X7 antagonists have
been valuable tools for investigating P2X7 in vivo, the
following considerations may prove useful in future
studies. First, the use of more selective P2X7 antagonists will support the current in vivo literature proposing a role for P2X7 in disease and injury. However,
this may be limited for many laboratories because of the
lack of availability or high cost of such antagonists.
Second, although a number of commonly used antagonists are branded as P2X7 specific, there is still an
absence of comprehensive information on the specificity
of these compounds against other P2 receptor members,
especially for mouse P2X7. In addition, data are lacking
on the effects of many of these antagonists on recombinant murine variants. It will be important to obtain more
complete pharmacological profiles for some of the widely
used P2X7 antagonists, as previously done at a number
of human and rat P2X subtypes (Bianchi et al., 1999;
Donnelly-Roberts et al., 2009). Third, the generation of a
complete P2X7 KO mouse, to negate the effect of escaped
P2X7 variants, will be of value for future investigations.
Fourth, the use of P2X7 antagonists in conjunction with
various KO mice may be useful for determining the
mechanisms of P2X7 action in vivo. For example, the use
of the P2X7 antagonist A839977 in IL-1ab KO mice,
which lack genes for both IL-1a and IL-1b, has suggested
that the positive effects of P2X7 inhibition in inflammatory pain models are mediated by blocking IL-1b release
(Honore et al., 2009). Fifth, with the emergence of
biologics (therapeutic antibodies) (Hatcher et al., 2011),
anti-P2X7 antibodies represent promising tools for investigating the roles of P2X7 in disease and injury. In
this regard, an anti-P2X7 monoclonal antibody was
recently generated and demonstrated to inhibit mast
cell activation and prevent the resulting intestinal inflammation in mice (Kurashima et al., 2012). Moreover,
an anti-P2X7 monoclonal antibody has long been known
to impair human P2X7 (Buell et al., 1998). Of note, this
same antibody is capable of binding to rat and guinea pig
P2X7 in transfected HEK-293 and human osteosarcoma
U-2 OS cells (Smart et al., 2003; Fonfria et al., 2008), but
whether this antibody is capable of blocking the activation
of this receptor in these species remains unknown.
Furthermore, single-domain antibodies, or nanobodies,
have been shown to be promising tools for inhibiting
specific membrane proteins (Pardon et al., 2014). In one
pioneer study, an ART2.2-specific single-domain antibody
was generated and shown to completely block ART2.2
enzymatic activity and NAD-induced cytotoxicity in vivo
(Koch-Nolte et al., 2007). Thus, these antibodies could be

used indirectly and reversibly to block P2X7 activation
in mice. Likewise, this same technology is being applied to develop single-domain antibodies to P2X7 to
directly target or inhibit this receptor (Laeremans
et al., 2010). Finally, despite the development and
patenting of a number of P2X7 antagonists for the
treatment of human disease (Gunosewoyo and Kassiou,
2010), we are still awaiting results on the efficacy of
many of these antagonists in humans, as well as the
outcomes of current clinical trials, which will further
influence future attempts to target P2X7.
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